<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta
            http-equiv="Content-Style-Type" content="text/css" /><meta
            name="description" content="P-001 - Clinical Study Protocol
            (template); version 27-Nov-2012" /><meta name="keywords"
            content="LEO R&amp;D Template" /><meta name="generator"
            content="Aspose.Words for Python via .NET 23.1.0" /><title>Clinical
            Study Protocol (template)</title></head><body
        style="font-family:'Times New Roman'; font-size:12pt"><div><div
                style="-aw-headerfooter-type:header-primary; clear:both"><p
                    style="margin-top:0pt; margin-bottom:0pt"><span
                        style="width:456pt; height:248pt; display:block"><span
                            style="height:0pt; display:block; position:absolute;
                            z-index:-65546"><img src="Output.001.png"
                                width="609" height="331" alt=""
                                style="margin-top:254.68pt; -aw-left-pos:0pt;
                                -aw-rel-hpos:margin; -aw-rel-vpos:margin;
                                -aw-top-pos:0pt; -aw-wrap-type:none;
                                position:absolute" /></span></span></p></div><p
                style="margin-top:0pt; margin-bottom:0pt"><span
                    style="font-weight:bold; color:#ff0000">Evaluation Only..</span></p><p
                style="margin:25.9pt 116.7pt 0pt 127.1pt; text-align:center;
                line-height:45.35pt"><span style="font-family:Calibri;
                    font-size:14pt; font-weight:bold">Non-Interventional Study
                    Protocol Study Short Title</span><span
                    style="font-family:Calibri; font-size:14pt;
                    font-weight:bold; -aw-import:spaces">&#xa0; </span></p><p
                style="margin:24pt 5.25pt 0pt 15.6pt; text-align:right;
                line-height:21.35pt"><span style="font-family:Calibri;
                    font-size:14pt; font-weight:bold">Evaluation of the
                    sensitivity and specificity of a novel quality of life (QoL)
                    tool to assess the treatment satisfaction in psoriasis
                    patients </span></p><p style="margin:1.95pt 106.4pt 0pt
                116.3pt; text-align:center; line-height:45.35pt"><span
                    style="font-family:Calibri; font-weight:bold">STUDY
                    IDENTIFICATION </span><span style="font-family:Calibri;
                    font-weight:bold; letter-spacing:0.05pt">No</span><span
                    style="font-family:Calibri; font-size:14pt;
                    font-weight:bold; letter-spacing:0.05pt">.</span><span
                    style="font-family:Calibri"> </span><span
                    style="font-family:Calibri; font-weight:bold">2020-A00652-37
                    Full Study Title </span></p><p style="margin-top:24.15pt;
                margin-left:5.75pt; margin-bottom:0pt; text-align:center;
                line-height:18.2pt"><span style="font-family:Calibri">Evaluation
                    of the sensitivity and specificity, compared to DLQI as a
                    standard tool, of a novel QoL questionnaire (treat to the
                    PSOriasis patient satiSfactiOn TARGET) among moderate to
                    severe psoriasis patients treated with brodalumab
                    (Kyntheum®) </span></p><p style="margin-top:27.65pt;
                margin-bottom:0pt; text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri; font-weight:bold">GPP statement:</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri; font-style:italic;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri; font-style:italic">This
                    Non-Interventional Study will be conducted in compliance
                    with the </span></p><p style="margin-top:0.05pt;
                margin-left:113.3pt; margin-bottom:0pt; line-height:18.35pt"><span
                    style="font-family:Calibri; font-style:italic">Clinical</span><span
                    style="font-family:Calibri; font-style:italic;
                    -aw-import:spaces">&#xa0; </span><span
                    style="font-family:Calibri; font-style:italic">Study</span><span
                    style="font-family:Calibri; font-style:italic;
                    -aw-import:spaces">&#xa0; </span><span
                    style="font-family:Calibri; font-style:italic">Protocol,
                </span><span style="font-family:Calibri; font-style:italic;
                    letter-spacing:0.1pt; -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri; font-style:italic">Good</span><span
                    style="font-family:Calibri; font-style:italic;
                    -aw-import:spaces">&#xa0; </span><span
                    style="font-family:Calibri; font-style:italic">Pharmacoepidemiology</span><span
                    style="font-family:Calibri; font-style:italic;
                    -aw-import:spaces">&#xa0; </span><span
                    style="font-family:Calibri; font-style:italic">Practices</span><span
                    style="font-family:Calibri; font-style:italic;
                    -aw-import:spaces">&#xa0; </span><span
                    style="font-family:Calibri; font-style:italic">and
                    applicable regulatory requirement(s). </span></p><p
                style="margin:28.7pt 42.15pt 0pt 5.4pt; line-height:18.35pt"><span
                    style="font-family:Calibri; font-weight:bold">Sponsoring
                    entity:</span><span style="font-family:Calibri;
                    font-weight:bold; font-style:italic"> </span><span
                    style="font-family:Calibri; font-weight:bold;
                    letter-spacing:159.85pt; -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri; font-weight:bold">LEO Study ID:</span><span
                    style="font-family:Calibri; font-weight:bold;
                    -aw-import:spaces">&#xa0; </span><span
                    style="font-family:Calibri; font-weight:bold">PSO-TARGET LEO
                    Pharma France</span><span style="font-family:Calibri;
                    font-weight:bold; -aw-import:spaces">&#xa0; </span></p><p
                style="margin:0.25pt 48.3pt 0pt 19.8pt; line-height:18.45pt"><span
                    style="font-family:Calibri">2 rue René Caudron</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri; font-weight:bold;
                    letter-spacing:177pt; -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri; font-weight:bold">Date:</span><span
                    style="font-family:Calibri; font-weight:bold;
                    -aw-import:spaces">&#xa0; </span><span
                    style="font-family:Calibri; font-weight:bold">25-05-2020
                </span><span style="font-family:Calibri">215 avenue Georges
                    Clemenceau </span></p><p style="margin-top:3.4pt;
                margin-left:19.8pt; margin-bottom:0pt; text-align:justify;
                line-height:14.6pt"><span style="font-family:Calibri">78960
                    Voisins-Le-Bretonneux </span></p><p
                style="margin-top:21.3pt; margin-left:287.8pt;
                margin-bottom:0pt; text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri; font-weight:bold">Version:</span><span
                    style="font-family:Calibri; font-weight:bold;
                    -aw-import:spaces">&#xa0; </span><span
                    style="font-family:Calibri; font-weight:bold">2.0 </span></p><div
                style="-aw-headerfooter-type:footer-primary; clear:both"><p
                    style="margin-top:0pt; margin-bottom:0pt"><span
                        style="font-weight:bold; color:#ff0000">Created with an
                        evaluation copy of Aspose.Words. To discover the full
                        versions of our APIs please visit:
                        https://products.aspose.com/words/</span></p></div></div><br
            style="page-break-before:always; clear:both;
            mso-break-type:section-break" /><div><div
                style="-aw-headerfooter-type:header-primary; clear:both"><p
                    style="margin-top:0pt; margin-bottom:0pt"><span
                        style="height:0pt; display:block; position:absolute;
                        z-index:-65545"><img src="Output.002.png" width="636"
                            height="346" alt="" style="margin-top:231.05pt;
                            -aw-left-pos:0pt; -aw-rel-hpos:margin;
                            -aw-rel-vpos:margin; -aw-top-pos:0pt;
                            -aw-wrap-type:none; position:absolute" /></span><span
                        style="-aw-import:ignore">&#xa0;</span></p></div><p
                style="margin-top:2.95pt; margin-left:0.05pt;
                margin-bottom:32.15pt; text-align:justify; line-height:13.45pt"><span
                    style="font-family:Calibri; font-size:11pt;
                    font-weight:bold">KEY STUDY PERSONNEL </span></p><div
                style="-aw-headerfooter-type:footer-primary; clear:both"><p
                    style="margin-top:0pt; margin-bottom:0pt"><span
                        style="font-weight:bold; color:#ff0000">Created with an
                        evaluation copy of Aspose.Words. To discover the full
                        versions of our APIs please visit:
                        https://products.aspose.com/words/</span></p><p
                    style="margin:0pt 21pt 0pt 48.05pt; line-height:6.95pt"><span
                        style="height:0pt; display:block; position:absolute;
                        z-index:-65541"><img src="Output.004.png" width="46"
                            height="29" alt="" style="margin-top:-7.08pt;
                            margin-left:-44.55pt; -aw-left-pos:74.4pt;
                            -aw-rel-hpos:page; -aw-rel-vpos:paragraph;
                            -aw-top-pos:-0.13pt; -aw-wrap-type:none;
                            position:absolute" /></span><span style="height:0pt;
                        display:block; position:absolute; z-index:-65542"><img
                            src="Output.003.png" width="4" height="35" alt=""
                            style="margin-top:-8.88pt; margin-left:-4.95pt;
                            -aw-left-pos:114pt; -aw-rel-hpos:page;
                            -aw-rel-vpos:paragraph; -aw-top-pos:-1.93pt;
                            -aw-wrap-type:none; position:absolute" /></span><span
                        style="font-size:6pt">THIS DOCUMENT CONTAINS TRADE
                        SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION,
                        PRIVILEGED OR CONFIDENTIAL, </span><span
                        style="font-size:6pt; letter-spacing:0.05pt">DELI-
                    </span><span style="font-size:6pt">VERED IN CONFIDENCE AND
                        RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR
                        MADE AVAILABLE TO ANY THIRD PARTY WITHOUT THE WRITTEN
                        CONSENT OF LEO PHARMA A/S </span></p></div></div><br
            style="clear:both; mso-break-type:section-break" /><div><p
                style="margin-top:0.05pt; margin-left:5.4pt; margin-bottom:0pt;
                text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri; font-weight:bold">STUDY MANAGER
                </span></p><p style="margin-top:3.65pt; margin-left:5.4pt;
                margin-bottom:0pt; text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri">BERTRAND Bénédicte, Clinical
                    Manager </span></p><p style="margin-top:22.1pt;
                margin-left:5.4pt; margin-bottom:0pt; text-align:justify;
                line-height:14.6pt"><span style="font-family:Calibri;
                    font-weight:bold">CLINACT</span><span
                    style="font-family:Calibri; font-weight:bold;
                    -aw-import:spaces">&#xa0; </span></p><p
                style="margin-top:0.05pt; margin-left:5.4pt; margin-bottom:0pt;
                line-height:18.35pt"><span style="font-family:Calibri">Vélizy
                    Espace – Immeuble Santos Dumont 13 avenue Morane Saulnier –
                    CS 50730 78457 Vélizy-Villacoublay Cedex, France </span></p><p
                style="margin-top:0.05pt; margin-bottom:0pt; text-align:justify;
                line-height:14.6pt"><br style="clear:both;
                    mso-column-break-before:always" /><span
                    style="font-family:Calibri; font-weight:bold">MAIN PROTOCOL
                    AUTHOR </span></p><p style="margin-top:3.65pt;
                margin-bottom:0pt; text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri">SALTET DE SABLET Thibaut,
                    Medical Writer </span></p><p style="margin-top:22.1pt;
                margin-bottom:0pt; text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri; font-weight:bold">CLINACT
                </span></p><p style="margin-top:0.05pt; margin-bottom:21.95pt;
                line-height:18.35pt"><span style="font-family:Calibri">Vélizy
                    Espace – Immeuble Santos Dumont 13 avenue Morane Saulnier –
                    CS 50730 78457 Vélizy-Villacoublay Cedex, France </span></p></div><br
            style="clear:both; mso-break-type:section-break" /><div><div
                style="-aw-headerfooter-type:header-primary; clear:both"><p
                    style="margin-top:0pt; margin-bottom:0pt"><span
                        style="height:0pt; display:block; position:absolute;
                        z-index:-65543"><img src="Output.002.png" width="636"
                            height="346" alt="" style="margin-top:231.05pt;
                            -aw-left-pos:0pt; -aw-rel-hpos:margin;
                            -aw-rel-vpos:margin; -aw-top-pos:0pt;
                            -aw-wrap-type:none; position:absolute" /></span><span
                        style="-aw-import:ignore">&#xa0;</span></p></div><p
                style="margin-top:0.05pt; margin-left:5.45pt; margin-bottom:0pt;
                text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri; font-weight:bold">STATISTICIAN
                </span></p><p style="margin:0.05pt 243.05pt 0pt 5.45pt;
                line-height:18.35pt"><span style="font-family:Calibri">CARRERE</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">Florence,</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">Head</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">of</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">Biometry</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">/ Senior
                    Biostatistician </span></p><p style="margin-top:21.95pt;
                margin-left:5.45pt; margin-bottom:0pt; text-align:justify;
                line-height:14.6pt"><span style="font-family:Calibri;
                    font-weight:bold">STATITEC </span></p><p
                style="margin:0.05pt 259.05pt 0pt 5.45pt; line-height:18.35pt"><span
                    style="font-family:Calibri">Vélizy Espace – Immeuble Santos
                    Dumont 13 avenue Morane Saulnier – CS 50730 78457
                    Vélizy-Villacoublay Cedex, France </span></p><p
                style="margin-top:2.95pt; margin-left:0.05pt; margin-bottom:0pt;
                text-align:justify; line-height:13.45pt"><br
                    style="page-break-before:always; clear:both" /><span
                    style="font-family:Calibri; font-size:11pt;
                    font-weight:bold">APPROVERS</span><span
                    style="font-family:Calibri; font-size:11pt"> </span></p><p
                style="margin:5.8pt 9.95pt 0pt 0.05pt; text-align:justify;
                line-height:18.2pt"><span style="height:0pt; margin-top:-5.8pt;
                    text-align:left; display:block; position:absolute;
                    z-index:0"><img src="Output.005.png" width="376"
                        height="147" alt="" style="margin-top:3.37pt;
                        margin-left:0.05pt; -aw-left-pos:71pt;
                        -aw-rel-hpos:page; -aw-rel-vpos:paragraph;
                        -aw-top-pos:45.57pt; -aw-wrap-type:none;
                        position:absolute" /></span><span
                    style="font-family:Calibri">The following person(s) within
                    LEO Pharma (LEO) has/have approved this Study Protocol by
                    signing the Non-Interventional Study Protocol Approval Form
                    adjoined as a separate page to this document:</span><span
                    style="font-family:Calibri; font-style:italic"> </span></p><p
                style="margin-top:32.55pt; margin-left:10.85pt;
                margin-bottom:0pt; text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri; font-weight:bold">Nadine
                    MacKenzie </span></p><p style="margin-top:4.1pt;
                margin-left:10.85pt; margin-bottom:0pt; text-align:justify;
                line-height:14.6pt"><span style="height:0pt; margin-top:-4.1pt;
                    text-align:left; display:block; position:absolute;
                    z-index:1"><img src="Output.006.png" width="323" height="4"
                        alt="" style="margin-top:2.56pt; margin-left:-6.75pt;
                        -aw-left-pos:75pt; -aw-rel-hpos:page;
                        -aw-rel-vpos:paragraph; -aw-top-pos:2.56pt;
                        -aw-wrap-type:none; position:absolute" /></span><span
                    style="font-family:Calibri">Medical director, France and
                    Benelux</span><span style="font-family:Calibri;
                    -aw-import:spaces">&#xa0; </span></p><p
                style="margin-top:40.4pt; margin-left:10.85pt;
                margin-bottom:0pt; text-align:justify; line-height:14.6pt"><span
                    style="height:0pt; margin-top:-40.4pt; text-align:left;
                    display:block; position:absolute; z-index:2"><img
                        src="Output.005.png" width="376" height="147" alt=""
                        style="margin-top:-80.93pt; margin-left:-10.75pt;
                        -aw-left-pos:71pt; -aw-rel-hpos:page;
                        -aw-rel-vpos:paragraph; -aw-top-pos:-80.93pt;
                        -aw-wrap-type:none; position:absolute" /></span><span
                    style="height:0pt; margin-top:-40.4pt; text-align:left;
                    display:block; position:absolute; z-index:-5"><img
                        src="Output.007.png" width="98" height="83" alt=""
                        style="margin-top:23.26pt; margin-left:245.2pt;
                        -aw-left-pos:326.95pt; -aw-rel-hpos:page;
                        -aw-rel-vpos:paragraph; -aw-top-pos:23.26pt;
                        -aw-wrap-type:none; position:absolute" /></span><span
                    style="font-family:Calibri; font-weight:bold">Sarah Moumane
                </span><span style="font-family:Calibri; font-weight:bold;
                    -aw-import:spaces">&#xa0;</span></p><p
                style="margin-top:4.25pt; margin-left:10.85pt;
                margin-bottom:0pt; text-align:justify; line-height:14.6pt"><span
                    style="height:0pt; margin-top:-4.25pt; text-align:left;
                    display:block; position:absolute; z-index:3"><img
                        src="Output.008.png" width="323" height="4" alt=""
                        style="margin-top:2.85pt; margin-left:-6.75pt;
                        -aw-left-pos:75pt; -aw-rel-hpos:page;
                        -aw-rel-vpos:paragraph; -aw-top-pos:2.85pt;
                        -aw-wrap-type:none; position:absolute" /></span><span
                    style="font-family:Calibri">Dermatology MSL manager, France
                </span><span style="font-family:Calibri; -aw-import:spaces">&#xa0;</span></p><p
                style="margin-top:50.8pt; margin-left:10.85pt;
                margin-bottom:0pt; text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri; font-weight:bold">Angèle GUILBOT
                </span></p><p style="margin:0.65pt 287.55pt 0pt 10.85pt;
                line-height:18.25pt"><span style="height:0pt;
                    margin-top:-0.65pt; display:block; position:absolute;
                    z-index:4"><img src="Output.010.png" width="320" height="4"
                        alt="" style="margin-top:-16.29pt; margin-left:-6.75pt;
                        -aw-left-pos:75pt; -aw-rel-hpos:page;
                        -aw-rel-vpos:paragraph; -aw-top-pos:2.61pt;
                        -aw-wrap-type:none; position:absolute" /></span><span
                    style="height:0pt; margin-top:-0.65pt; display:block;
                    position:absolute; z-index:-4"><img src="Output.009.png"
                        width="132" height="86" alt=""
                        style="margin-top:-14.64pt; margin-left:237.55pt;
                        -aw-left-pos:319.3pt; -aw-rel-hpos:page;
                        -aw-rel-vpos:paragraph; -aw-top-pos:4.26pt;
                        -aw-wrap-type:none; position:absolute" /></span><span
                    style="font-family:Calibri">Scientific and Regulatory
                    Director </span><span style="font-family:Calibri;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri; font-weight:bold">CLINACT
                </span><span style="font-family:Calibri; font-weight:bold;
                    -aw-import:spaces">&#xa0;</span></p><p style="margin:0.15pt
                247.3pt 0pt 10.85pt; line-height:18.2pt"><span
                    style="height:0pt; margin-top:-0.15pt; display:block;
                    position:absolute; z-index:-3"><img src="Output.011.png"
                        width="322" height="4" alt="" style="margin-top:20.96pt;
                        margin-left:-7.75pt; -aw-left-pos:74pt;
                        -aw-rel-hpos:page; -aw-rel-vpos:paragraph;
                        -aw-top-pos:57.51pt; -aw-wrap-type:none;
                        position:absolute" /></span><span
                    style="font-family:Calibri">Vélizy Espace – Immeuble Santos
                    Dumont </span><span style="font-family:Calibri;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">13 avenue Morane Saulnier – CS
                    50730 </span><span style="font-family:Calibri;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">78457 Vélizy-Villacoublay Cedex,
                    France</span><span style="font-family:Calibri;
                    font-style:italic"> </span></p><p style="margin-top:51.25pt;
                margin-left:10.85pt; margin-bottom:0pt; text-align:justify;
                line-height:14.6pt"><span style="font-family:Calibri;
                    font-weight:bold">Dr Ziad REGUIAI</span><span
                    style="font-family:Calibri"> </span></p><p
                style="margin:0.5pt 255pt 0pt 10.85pt; line-height:18.35pt"><span
                    style="height:0pt; margin-top:-0.5pt; display:block;
                    position:absolute; z-index:5"><img src="Output.013.png"
                        width="322" height="4" alt=""
                        style="margin-top:-16.18pt; margin-left:-6.75pt;
                        -aw-left-pos:75pt; -aw-rel-hpos:page;
                        -aw-rel-vpos:paragraph; -aw-top-pos:2.67pt;
                        -aw-wrap-type:none; position:absolute" /></span><span
                    style="height:0pt; margin-top:-0.5pt; display:block;
                    position:absolute; z-index:-2"><img src="Output.012.png"
                        width="125" height="82" alt=""
                        style="margin-top:-14.56pt; margin-left:237.75pt;
                        -aw-left-pos:319.5pt; -aw-rel-hpos:page;
                        -aw-rel-vpos:paragraph; -aw-top-pos:4.29pt;
                        -aw-wrap-type:none; position:absolute" /></span><span
                    style="font-family:Calibri">International Co-ordinating
                    Investigator</span><span style="font-family:Calibri;
                    -aw-import:spaces">&#xa0; </span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">Polyclinique Reims-Bezannes
                </span><span style="font-family:Calibri; -aw-import:spaces">&#xa0;</span></p><p
                style="margin-top:3.65pt; margin-left:10.85pt;
                margin-bottom:0pt; text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri">89 Rue Victor De Broglie </span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;</span></p><p
                style="margin-top:3.75pt; margin-left:10.85pt;
                margin-bottom:0pt; text-align:justify; line-height:14.6pt"><span
                    style="height:0pt; margin-top:-3.75pt; text-align:left;
                    display:block; position:absolute; z-index:-1"><img
                        src="Output.014.png" width="323" height="4" alt=""
                        style="margin-top:21.2pt; margin-left:-7.75pt;
                        -aw-left-pos:74pt; -aw-rel-hpos:page;
                        -aw-rel-vpos:paragraph; -aw-top-pos:21.2pt;
                        -aw-wrap-type:none; position:absolute" /></span><span
                    style="font-family:Calibri">51430 Bezannes, FRANCE </span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;</span></p><p
                style="margin-top:3.05pt; margin-left:35.55pt;
                margin-bottom:0pt; text-align:justify; line-height:17.1pt"><br
                    style="page-break-before:always; clear:both" /><a
                    name="_page3_x68.00_y96.92"></a><span
                    style="font-family:Calibri; font-size:14pt;
                    font-weight:bold">1</span><span style="font-family:Arial;
                    font-size:14pt; font-weight:bold"> </span><span
                    style="font-family:Calibri; font-size:14pt;
                    font-weight:bold; letter-spacing:15.5pt; -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri; font-size:14pt;
                    font-weight:bold">Table of Contents </span></p><p
                style="margin:19.4pt 13.05pt 0pt 0.05pt; text-align:justify;
                line-height:23.75pt"><a href="#_page3_x68.00_y96.92"
                    style="text-decoration:none"><span
                        style="font-family:Calibri; color:#0000ff">1</span><span
                        style="font-family:Calibri; letter-spacing:5.25pt;
                        color:#0000ff"> </span><span style="font-family:Calibri;
                        color:#0000ff">Table of Contents
                        ...................................................................................................................
                        4 </span></a><a href="#_page6_x68.00_y96.92"
                    style="text-decoration:none"><span
                        style="font-family:Calibri; color:#0000ff">2</span><span
                        style="font-family:Calibri; letter-spacing:5.25pt;
                        color:#0000ff"> </span><span style="font-family:Calibri;
                        color:#0000ff">List of Abbreviations
                        ..............................................................................................................
                        7 </span></a><a href="#_page7_x68.00_y96.92"
                    style="text-decoration:none"><span
                        style="font-family:Calibri; color:#0000ff">3</span><span
                        style="font-family:Calibri; letter-spacing:5.25pt;
                        color:#0000ff"> </span><span style="font-family:Calibri;
                        color:#0000ff">Responsible Parties
                        ................................................................................................................
                        8 </span></a><a href="#_page9_x68.00_y96.92"
                    style="text-decoration:none"><span
                        style="font-family:Calibri; color:#0000ff">4</span><span
                        style="font-family:Calibri; letter-spacing:5.25pt;
                        color:#0000ff"> </span><span style="font-family:Calibri;
                        color:#0000ff">Abstract
                        ................................................................................................................................
                        10 </span></a><a href="#_page14_x68.00_y568.92"
                    style="text-decoration:none"><span
                        style="font-family:Calibri; color:#0000ff">5</span><span
                        style="font-family:Calibri; letter-spacing:5.25pt;
                        color:#0000ff"> </span><span style="font-family:Calibri;
                        color:#0000ff">Amendments and Updates
                        ..................................................................................................
                        15 </span></a><a href="#_page15_x68.00_y96.92"
                    style="text-decoration:none"><span
                        style="font-family:Calibri; color:#0000ff">6</span><span
                        style="font-family:Calibri; letter-spacing:5.25pt;
                        color:#0000ff"> </span><span style="font-family:Calibri;
                        color:#0000ff">Milestones
                        ...........................................................................................................................
                        16 </span></a><a href="#_page15_x68.00_y392.92"
                    style="text-decoration:none"><span
                        style="font-family:Calibri; color:#0000ff">7</span><span
                        style="font-family:Calibri; letter-spacing:5.25pt;
                        color:#0000ff"> </span><span style="font-family:Calibri;
                        color:#0000ff">Rationale and Background
                        ...................................................................................................
                        16 </span></a><a href="#_page19_x68.00_y96.92"
                    style="text-decoration:none"><span
                        style="font-family:Calibri; color:#0000ff">8</span><span
                        style="font-family:Calibri; letter-spacing:5.25pt;
                        color:#0000ff"> </span><span style="font-family:Calibri;
                        color:#0000ff">Research Question and Objectives
                        ......................................................................................
                        20</span></a></p><p style="margin:3pt 13.05pt 0pt
                0.05pt; text-indent:0.2pt; text-align:justify;
                line-height:20.6pt"><img src="Output.015.png" width="20"
                    height="12" alt="" style="-aw-left-pos:0pt;
                    -aw-rel-hpos:column; -aw-rel-vpos:paragraph;
                    -aw-top-pos:0pt; -aw-wrap-type:inline" /><a
                    href="#_page19_x68.00_y123.92" style="text-decoration:none"><span
                        style="font-family:Calibri; letter-spacing:9.05pt;
                        color:#000000; -aw-import:spaces">&#xa0;</span><span
                        style="font-family:Calibri; color:#0000ff">Primary
                        Objective
                        ............................................................................................................
                        20 </span></a><img src="Output.016.png" width="20"
                    height="12" alt="" style="-aw-left-pos:0pt;
                    -aw-rel-hpos:column; -aw-rel-vpos:paragraph;
                    -aw-top-pos:0pt; -aw-wrap-type:inline" /><a
                    href="#_page19_x68.00_y291.92" style="text-decoration:none"><span
                        style="font-family:Calibri; letter-spacing:9.05pt;
                        color:#000000; -aw-import:spaces">&#xa0;</span><span
                        style="font-family:Calibri; color:#0000ff">Secondary
                        Objectives
                        ......................................................................................................
                        20 </span></a><a href="#_page19_x68.00_y611.92"
                    style="text-decoration:none"><span
                        style="font-family:Calibri; color:#0000ff">9</span><span
                        style="font-family:Calibri; letter-spacing:5.25pt;
                        color:#0000ff"> </span><span style="font-family:Calibri;
                        color:#0000ff">Research
                        Method.................................................................................................................
                        20</span></a></p><p style="margin:3.05pt 13.05pt 0pt
                0.25pt; text-align:justify; line-height:20.6pt"><img
                    src="Output.017.png" width="20" height="12" alt=""
                    style="-aw-left-pos:0pt; -aw-rel-hpos:column;
                    -aw-rel-vpos:paragraph; -aw-top-pos:0pt;
                    -aw-wrap-type:inline" /><a href="#_page19_x98.00_y638.92"
                    style="text-decoration:none"><span
                        style="font-family:Calibri; letter-spacing:9.05pt;
                        color:#000000; -aw-import:spaces">&#xa0;</span><span
                        style="font-family:Calibri; color:#0000ff">Study Design
                        ....................................................................................................................
                        20 </span></a><img src="Output.018.png" width="32"
                    height="12" alt="" style="-aw-left-pos:0pt;
                    -aw-rel-hpos:column; -aw-rel-vpos:paragraph;
                    -aw-top-pos:0pt; -aw-wrap-type:inline" /><a
                    href="#_page19_x68.00_y665.92" style="text-decoration:none"><span
                        style="font-family:Calibri; letter-spacing:11.85pt;
                        color:#000000; -aw-import:spaces">&#xa0;</span><span
                        style="font-family:Calibri; color:#0000ff">Eligibility
                        criteria
                        ..........................................................................................................
                        20 </span></a><img src="Output.019.png" width="32"
                    height="12" alt="" style="-aw-left-pos:0pt;
                    -aw-rel-hpos:column; -aw-rel-vpos:paragraph;
                    -aw-top-pos:0pt; -aw-wrap-type:inline" /><a
                    href="#_page20_x68.00_y356.92" style="text-decoration:none"><span
                        style="font-family:Calibri; letter-spacing:11.85pt;
                        color:#000000; -aw-import:spaces">&#xa0;</span><span
                        style="font-family:Calibri; color:#0000ff">PSO-TARGET
                        Quality of Life Component grid.
                        .............................................................
                        21 </span></a><img src="Output.020.png" width="32"
                    height="12" alt="" style="-aw-left-pos:0pt;
                    -aw-rel-hpos:column; -aw-rel-vpos:paragraph;
                    -aw-top-pos:0pt; -aw-wrap-type:inline" /><a
                    href="#_page21_x68.00_y620.92" style="text-decoration:none"><span
                        style="font-family:Calibri; letter-spacing:11.95pt;
                        color:#000000; -aw-import:spaces">&#xa0;</span><span
                        style="font-family:Calibri; color:#0000ff">Dermatology
                        Quality of Life Index (DLQI)
                        ....................................................................
                        22 </span></a><img src="Output.021.png" width="32"
                    height="12" alt="" style="-aw-left-pos:0pt;
                    -aw-rel-hpos:column; -aw-rel-vpos:paragraph;
                    -aw-top-pos:0pt; -aw-wrap-type:inline" /><a
                    href="#_page22_x68.00_y420.92" style="text-decoration:none"><span
                        style="font-family:Calibri; letter-spacing:11.6pt;
                        color:#000000; -aw-import:spaces">&#xa0;</span><span
                        style="font-family:Calibri; color:#0000ff">Limitation of
                        bias
                        .........................................................................................................
                        23 </span></a><img src="Output.022.png" width="32"
                    height="12" alt="" style="-aw-left-pos:0pt;
                    -aw-rel-hpos:column; -aw-rel-vpos:paragraph;
                    -aw-top-pos:0pt; -aw-wrap-type:inline" /><a
                    href="#_page22_x68.00_y554.92" style="text-decoration:none"><span
                        style="font-family:Calibri; letter-spacing:11.95pt;
                        color:#000000; -aw-import:spaces">&#xa0;</span><span
                        style="font-family:Calibri; color:#0000ff">Study
                        Schedule
                        ............................................................................................................
                        23</span></a></p><p style="margin:0.05pt 13.05pt 0pt
                0.25pt; text-align:justify; line-height:17.6pt"><img
                    src="Output.023.png" width="32" height="12" alt=""
                    style="-aw-left-pos:0pt; -aw-rel-hpos:column;
                    -aw-rel-vpos:paragraph; -aw-top-pos:0pt;
                    -aw-wrap-type:inline" /><a href="#_page23_x68.00_y512.92"
                    style="text-decoration:none"><span
                        style="font-family:Calibri; letter-spacing:11.7pt;
                        color:#000000; -aw-import:spaces">&#xa0;</span><span
                        style="font-family:Calibri; color:#0000ff">Definition of
                        a non-interventional study
                        .....................................................................
                        24 </span></a><img src="Output.024.png" width="20"
                    height="12" alt="" style="-aw-left-pos:0pt;
                    -aw-rel-hpos:column; -aw-rel-vpos:paragraph;
                    -aw-top-pos:0pt; -aw-wrap-type:inline" /><a
                    href="#_page24_x98.00_y188.92" style="text-decoration:none"><span
                        style="font-family:Calibri; letter-spacing:9.05pt;
                        color:#000000; -aw-import:spaces">&#xa0;</span><span
                        style="font-family:Calibri; color:#0000ff">Setting
                        ..............................................................................................................................
                        25</span></a></p><p style="margin:0.05pt 13.05pt 0pt
                0.25pt; text-align:justify; line-height:20.65pt"><img
                    src="Output.025.png" width="20" height="12" alt=""
                    style="-aw-left-pos:0pt; -aw-rel-hpos:column;
                    -aw-rel-vpos:paragraph; -aw-top-pos:0pt;
                    -aw-wrap-type:inline" /><a href="#_page25_x98.00_y96.92"
                    style="text-decoration:none"><span
                        style="font-family:Calibri; letter-spacing:9.2pt;
                        color:#000000; -aw-import:spaces">&#xa0;</span><span
                        style="font-family:Calibri; color:#0000ff">Variables
                        ..........................................................................................................................
                        26 </span></a><img src="Output.026.png" width="20"
                    height="12" alt="" style="-aw-left-pos:0pt;
                    -aw-rel-hpos:column; -aw-rel-vpos:paragraph;
                    -aw-top-pos:0pt; -aw-wrap-type:inline" /><a
                    href="#_page27_x98.00_y485.92" style="text-decoration:none"><span
                        style="font-family:Calibri; letter-spacing:8.85pt;
                        color:#000000; -aw-import:spaces">&#xa0;</span><span
                        style="font-family:Calibri; color:#0000ff">Data Source
                        .....................................................................................................................
                        28 </span></a><img src="Output.027.png" width="20"
                    height="12" alt="" style="-aw-left-pos:0pt;
                    -aw-rel-hpos:column; -aw-rel-vpos:paragraph;
                    -aw-top-pos:0pt; -aw-wrap-type:inline" /><a
                    href="#_page28_x98.00_y462.92" style="text-decoration:none"><span
                        style="font-family:Calibri; letter-spacing:9.2pt;
                        color:#000000; -aw-import:spaces">&#xa0;</span><span
                        style="font-family:Calibri; color:#0000ff">Study Size
                        .........................................................................................................................
                        29 </span></a><img src="Output.028.png" width="20"
                    height="12" alt="" style="-aw-left-pos:0pt;
                    -aw-rel-hpos:column; -aw-rel-vpos:paragraph;
                    -aw-top-pos:0pt; -aw-wrap-type:inline" /><a
                    href="#_page29_x68.00_y447.92" style="text-decoration:none"><span
                        style="font-family:Calibri; letter-spacing:8.95pt;
                        color:#000000; -aw-import:spaces">&#xa0;</span><span
                        style="font-family:Calibri; color:#0000ff">Data
                        Management
                        ...........................................................................................................
                        30 </span></a><img src="Output.029.png" width="20"
                    height="12" alt="" style="-aw-left-pos:0pt;
                    -aw-rel-hpos:column; -aw-rel-vpos:paragraph;
                    -aw-top-pos:0pt; -aw-wrap-type:inline" /><a
                    href="#_page31_x68.00_y96.92" style="text-decoration:none"><span
                        style="font-family:Calibri; letter-spacing:8.95pt;
                        color:#000000; -aw-import:spaces">&#xa0;</span><span
                        style="font-family:Calibri; color:#0000ff">Data Analysis
                        ...................................................................................................................
                        32 </span></a><img src="Output.030.png" width="20"
                    height="12" alt="" style="-aw-left-pos:0pt;
                    -aw-rel-hpos:column; -aw-rel-vpos:paragraph;
                    -aw-top-pos:0pt; -aw-wrap-type:inline" /><a
                    href="#_page31_x68.00_y306.92" style="text-decoration:none"><span
                        style="font-family:Calibri; letter-spacing:8.95pt;
                        color:#000000; -aw-import:spaces">&#xa0;</span><span
                        style="font-family:Calibri; color:#0000ff">Statistical
                        Analysis
                        Plan....................................................................................................
                        32</span></a></p><p style="margin:3pt 13.05pt 0pt
                0.25pt; text-align:justify; line-height:17.6pt"><img
                    src="Output.031.png" width="32" height="12" alt=""
                    style="-aw-left-pos:0pt; -aw-rel-hpos:column;
                    -aw-rel-vpos:paragraph; -aw-top-pos:0pt;
                    -aw-wrap-type:inline" /><a href="#_page31_x68.00_y531.92"
                    style="text-decoration:none"><span
                        style="font-family:Calibri; letter-spacing:11.85pt;
                        color:#000000; -aw-import:spaces">&#xa0;</span><span
                        style="font-family:Calibri; color:#0000ff">Description
                        of the population
                        .....................................................................................
                        32 </span></a><img src="Output.032.png" width="32"
                    height="12" alt="" style="-aw-left-pos:0pt;
                    -aw-rel-hpos:column; -aw-rel-vpos:paragraph;
                    -aw-top-pos:0pt; -aw-wrap-type:inline" /><a
                    href="#_page32_x68.00_y96.92" style="text-decoration:none"><span
                        style="font-family:Calibri; letter-spacing:11.85pt;
                        color:#000000; -aw-import:spaces">&#xa0;</span><span
                        style="font-family:Calibri; color:#0000ff">Baseline
                        characteristics
                        ...............................................................................................
                        33 </span></a><img src="Output.033.png" width="32"
                    height="12" alt="" style="-aw-left-pos:0pt;
                    -aw-rel-hpos:column; -aw-rel-vpos:paragraph;
                    -aw-top-pos:0pt; -aw-wrap-type:inline" /><a
                    href="#_page32_x109.00_y211.92"
                    style="text-decoration:none"><span
                        style="font-family:Calibri; letter-spacing:11.95pt;
                        color:#000000; -aw-import:spaces">&#xa0;</span><span
                        style="font-family:Calibri; color:#0000ff">Sensitivity/sensibility
                        analysis
                        .....................................................................................
                        33 </span></a><img src="Output.034.png" width="32"
                    height="12" alt="" style="-aw-left-pos:0pt;
                    -aw-rel-hpos:column; -aw-rel-vpos:paragraph;
                    -aw-top-pos:0pt; -aw-wrap-type:inline" /><a
                    href="#_page34_x68.00_y334.92" style="text-decoration:none"><span
                        style="font-family:Calibri; letter-spacing:11.6pt;
                        color:#000000; -aw-import:spaces">&#xa0;</span><span
                        style="font-family:Calibri; color:#0000ff">Efficacy
                        analysis
                        ...........................................................................................................
                        35</span></a><img src="Output.035.png" width="32"
                    height="12" alt="" style="-aw-left-pos:0pt;
                    -aw-rel-hpos:column; -aw-rel-vpos:paragraph;
                    -aw-top-pos:0pt; -aw-wrap-type:inline" /><a
                    href="#_page35_x68.00_y522.92" style="text-decoration:none"><span
                        style="font-family:Calibri; letter-spacing:11.95pt;
                        color:#000000; -aw-import:spaces">&#xa0;</span><span
                        style="font-family:Calibri; color:#0000ff">Other
                        secondary analyses
                        ...........................................................................................
                        36 </span></a><img src="Output.036.png" width="32"
                    height="12" alt="" style="-aw-left-pos:0pt;
                    -aw-rel-hpos:column; -aw-rel-vpos:paragraph;
                    -aw-top-pos:0pt; -aw-wrap-type:inline" /><a
                    href="#_page38_x68.00_y184.92" style="text-decoration:none"><span
                        style="font-family:Calibri; letter-spacing:11.7pt;
                        color:#000000; -aw-import:spaces">&#xa0;</span><span
                        style="font-family:Calibri; color:#0000ff">Safety
                        analysis
                        .............................................................................................................
                        39 </span></a><img src="Output.037.png" width="20"
                    height="12" alt="" style="-aw-left-pos:0pt;
                    -aw-rel-hpos:column; -aw-rel-vpos:paragraph;
                    -aw-top-pos:0pt; -aw-wrap-type:inline" /><a
                    href="#_page38_x98.00_y320.92" style="text-decoration:none"><span
                        style="font-family:Calibri; letter-spacing:9.05pt;
                        color:#000000; -aw-import:spaces">&#xa0;</span><span
                        style="font-family:Calibri; color:#0000ff">Quality
                        Control
                        ................................................................................................................
                        39</span></a></p><p style="margin:3.05pt 13.05pt 0pt
                0.25pt; text-align:justify; line-height:17.6pt"><img
                    src="Output.038.png" width="32" height="12" alt=""
                    style="-aw-left-pos:0pt; -aw-rel-hpos:column;
                    -aw-rel-vpos:paragraph; -aw-top-pos:0pt;
                    -aw-wrap-type:inline" /><a href="#_page38_x68.00_y457.92"
                    style="text-decoration:none"><span
                        style="font-family:Calibri; letter-spacing:11.85pt;
                        color:#000000; -aw-import:spaces">&#xa0;</span><span
                        style="font-family:Calibri; color:#0000ff">Data
                        Collection
                        ............................................................................................................
                        39 </span></a><img src="Output.039.png" width="32"
                    height="12" alt="" style="-aw-left-pos:0pt;
                    -aw-rel-hpos:column; -aw-rel-vpos:paragraph;
                    -aw-top-pos:0pt; -aw-wrap-type:inline" /><a
                    href="#_page38_x68.00_y627.92" style="text-decoration:none"><span
                        style="font-family:Calibri; letter-spacing:11.85pt;
                        color:#000000; -aw-import:spaces">&#xa0;</span><span
                        style="font-family:Calibri; color:#0000ff">Data
                        monitoring...........................................................................................................
                        39</span></a></p><p style="margin:0.05pt 13.05pt 0pt
                0.25pt; text-align:justify; line-height:17.6pt"><img
                    src="Output.040.png" width="32" height="12" alt=""
                    style="-aw-left-pos:0pt; -aw-rel-hpos:column;
                    -aw-rel-vpos:paragraph; -aw-top-pos:0pt;
                    -aw-wrap-type:inline" /><a href="#_page39_x68.00_y169.92"
                    style="text-decoration:none"><span
                        style="font-family:Calibri; letter-spacing:11.95pt;
                        color:#000000; -aw-import:spaces">&#xa0;</span><span
                        style="font-family:Calibri; color:#0000ff">Data
                        validation
                        .............................................................................................................
                        40 </span></a><img src="Output.041.png" width="28"
                    height="12" alt="" style="-aw-left-pos:0pt;
                    -aw-rel-hpos:column; -aw-rel-vpos:paragraph;
                    -aw-top-pos:0pt; -aw-wrap-type:inline" /><a
                    href="#_page39_x98.00_y413.92" style="text-decoration:none"><span
                        style="font-family:Calibri; letter-spacing:2.7pt;
                        color:#000000; -aw-import:spaces">&#xa0;</span><span
                        style="font-family:Calibri; color:#0000ff">Limitations
                        of Research Methods
                        ....................................................................................
                        40</span></a></p><p style="margin-top:6.05pt;
                margin-left:0.25pt; margin-bottom:0pt; text-align:justify"><img
                    src="Output.042.png" width="28" height="12" alt=""
                    style="-aw-left-pos:0pt; -aw-rel-hpos:column;
                    -aw-rel-vpos:paragraph; -aw-top-pos:0pt;
                    -aw-wrap-type:inline" /><a href="#_page40_x68.00_y159.92"
                    style="text-decoration:none"><span
                        style="font-family:Calibri; letter-spacing:2.95pt;
                        color:#000000; -aw-import:spaces">&#xa0;</span><span
                        style="font-family:Calibri; color:#0000ff">Other Aspects
                        ..................................................................................................................
                        41</span></a></p><p style="margin:0.05pt 13.05pt 0pt
                0.05pt; text-align:justify; line-height:23.75pt"><a
                    href="#_page40_x68.00_y566.92" style="text-decoration:none"><span
                        style="font-family:Calibri; color:#0000ff">10Protection
                        of human subjects
                        .............................................................................................
                        41 </span></a><a href="#_page43_x68.00_y127.92"
                    style="text-decoration:none"><span
                        style="font-family:Calibri; color:#0000ff">11Management
                        and Reporting of Adverse Events and Other Experiences
                        ............................ 44 </span></a><img
                    src="Output.043.png" width="28" height="12" alt=""
                    style="-aw-left-pos:0pt; -aw-rel-hpos:column;
                    -aw-rel-vpos:paragraph; -aw-top-pos:0pt;
                    -aw-wrap-type:inline" /><a href="#_page43_x68.00_y176.92"
                    style="text-decoration:none"><span
                        style="font-family:Calibri; letter-spacing:2.95pt;
                        color:#000000; -aw-import:spaces">&#xa0;</span><span
                        style="font-family:Calibri; color:#0000ff">Definitions
                        .......................................................................................................................
                        44</span></a></p><p style="margin-top:6pt;
                margin-left:0.75pt; margin-bottom:0pt; text-align:justify"><img
                    src="Output.044.png" width="28" height="12" alt=""
                    style="-aw-left-pos:0pt; -aw-rel-hpos:column;
                    -aw-rel-vpos:paragraph; -aw-top-pos:0pt;
                    -aw-wrap-type:inline" /><a href="#_page44_x68.00_y630.92"
                    style="text-decoration:none"><span
                        style="font-family:Calibri; letter-spacing:2.95pt;
                        color:#000000; -aw-import:spaces">&#xa0;</span><span
                        style="font-family:Calibri; color:#0000ff">Physician’s
                        responsibility for reporting of Adverse Drug Reactions,
                        Adverse Events and </span></a></p><p
                style="margin-top:0pt; margin-left:26.7pt; margin-bottom:0pt;
                text-align:justify; line-height:14.6pt"><a
                    href="#_page44_x68.00_y630.92" style="text-decoration:none"><span
                        style="font-family:Calibri; color:#0000ff">Other
                        Experiences
                        ...........................................................................................................
                        45</span></a></p><p style="margin:0.05pt 13.05pt 0pt
                0.05pt; text-indent:0.7pt; text-align:justify;
                line-height:20.6pt"><img src="Output.045.png" width="27"
                    height="12" alt="" style="-aw-left-pos:0pt;
                    -aw-rel-hpos:column; -aw-rel-vpos:paragraph;
                    -aw-top-pos:0pt; -aw-wrap-type:inline" /><a
                    href="#_page46_x68.00_y96.92" style="text-decoration:none"><span
                        style="font-family:Calibri; letter-spacing:3.05pt;
                        color:#000000; -aw-import:spaces">&#xa0;</span><span
                        style="font-family:Calibri; color:#0000ff">LEO
                        responsibilities for reporting of safety-related data
                        ................................................ 47
                    </span></a><a href="#_page46_x68.00_y233.92"
                    style="text-decoration:none"><span
                        style="font-family:Calibri; color:#0000ff">12Plans for
                        Disseminating and Communicating Study Results
                        ............................................... 47
                    </span></a><a href="#_page47_x68.00_y96.92"
                    style="text-decoration:none"><span
                        style="font-family:Calibri; color:#0000ff">13References
                        ...........................................................................................................................
                        48 </span></a><a href="#_page50_x68.00_y168.92"
                    style="text-decoration:none"><span
                        style="font-family:Calibri; color:#0000ff">Annex 1.
                        PSO-TARGET Component Grid
                        ...................................................................................
                        51</span></a></p><p style="margin-top:2.95pt;
                margin-left:0.05pt; margin-bottom:0pt; text-align:justify;
                line-height:14.6pt"><br style="page-break-before:always;
                    clear:both" /><span style="font-family:Calibri;
                    font-weight:bold">APPENDICES </span></p><p
                style="margin-top:32.45pt; margin-left:0.05pt;
                margin-bottom:0pt; text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri">1.</span><span
                    style="font-family:Arial"> </span><span
                    style="font-family:Calibri; letter-spacing:12.55pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">PSO-TARGET Component grid
                </span></p><p style="margin-top:3.05pt; margin-left:35.55pt;
                margin-bottom:0pt; text-align:justify; line-height:17.1pt"><br
                    style="page-break-before:always; clear:both" /><a
                    name="_page6_x68.00_y96.92"></a><span
                    style="font-family:Calibri; font-size:14pt;
                    font-weight:bold">2</span><span style="font-family:Arial;
                    font-size:14pt; font-weight:bold"> </span><span
                    style="font-family:Calibri; font-size:14pt;
                    font-weight:bold; letter-spacing:15.5pt; -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri; font-size:14pt;
                    font-weight:bold">List of Abbreviations </span></p><p
                style="margin-top:10.15pt; margin-left:0.05pt;
                margin-bottom:0pt; text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri">ADR: </span><span
                    style="font-family:Calibri; letter-spacing:35.75pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">Adverse Drug Reaction </span></p><p
                style="margin-top:3.65pt; margin-left:0.05pt; margin-bottom:0pt;
                text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri">AE: </span><span
                    style="font-family:Calibri; letter-spacing:43.75pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">Adverse Event </span></p><p
                style="margin-top:3.75pt; margin-left:0.05pt; margin-bottom:0pt;
                text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri">CRF: </span><span
                    style="font-family:Calibri; letter-spacing:38.15pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">Case Report Form </span></p><p
                style="margin-top:3.75pt; margin-left:0.05pt; margin-bottom:0pt;
                text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri">CRO: </span><span
                    style="font-family:Calibri; letter-spacing:35.75pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">Contract Research Organization
                </span></p><p style="margin-top:3.65pt; margin-left:0.05pt;
                margin-bottom:0pt; text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri">DLQI: </span><span
                    style="font-family:Calibri; letter-spacing:33.2pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">Dermatology Quality of Life
                    Index </span></p><p style="margin-top:3.75pt;
                margin-left:0.05pt; margin-bottom:0pt; text-align:justify;
                line-height:14.6pt"><span style="font-family:Calibri">HCP:
                </span><span style="font-family:Calibri; letter-spacing:36.45pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">Healthcare Practitioner </span></p><p
                style="margin-top:3.65pt; margin-left:0.05pt; margin-bottom:0pt;
                text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri">IEC: </span><span
                    style="font-family:Calibri; letter-spacing:41.35pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">Independent Ethics Committee
                </span></p><p style="margin-top:3.75pt; margin-left:0.05pt;
                margin-bottom:0pt; text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri">IRB: </span><span
                    style="font-family:Calibri; letter-spacing:40.4pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">Institutional Review Board
                </span></p><p style="margin:0.15pt 145.3pt 0pt 0.05pt;
                line-height:18.2pt"><span style="font-family:Calibri">LEO
                </span><span style="font-family:Calibri; letter-spacing:41pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">LEO Pharma A/S and/or affiliates
                    or representatives</span><span style="font-family:Calibri;
                    -aw-import:spaces">&#xa0; </span><span
                    style="font-family:Calibri">MedDRA: </span><span
                    style="font-family:Calibri; letter-spacing:13.15pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">Medical dictionary for
                    Regulatory Activities</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span></p><p style="margin-top:3.75pt; margin-left:0.05pt;
                margin-bottom:0pt; text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri">NIS: </span><span
                    style="font-family:Calibri; letter-spacing:40.3pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">Non-Interventional Study </span></p><p
                style="margin-top:3.65pt; margin-left:0.05pt; margin-bottom:0pt;
                text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri">OE: </span><span
                    style="font-family:Calibri; letter-spacing:42.7pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">Other Experience </span></p><p
                style="margin-top:3.75pt; margin-left:0.05pt; margin-bottom:0pt;
                text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri">PASI: </span><span
                    style="font-family:Calibri; letter-spacing:35.75pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">Psoriasis Area and Severity
                    Index</span><span style="font-family:Calibri;
                    -aw-import:spaces">&#xa0; </span></p><p
                style="margin-top:3.75pt; margin-left:0.05pt; margin-bottom:0pt;
                text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri">PRO: </span><span
                    style="font-family:Calibri; letter-spacing:35.95pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">Patient Reported Outcome </span></p><p
                style="margin-top:3.65pt; margin-left:0.05pt; margin-bottom:0pt;
                text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri">QoL: </span><span
                    style="font-family:Calibri; letter-spacing:37.05pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">Quality of Life </span></p><p
                style="margin-top:3.05pt; margin-left:35.55pt;
                margin-bottom:0pt; text-align:justify; line-height:17.1pt"><br
                    style="page-break-before:always; clear:both" /><a
                    name="_page7_x68.00_y96.92"></a><span
                    style="font-family:Calibri; font-size:14pt;
                    font-weight:bold">3</span><span style="font-family:Arial;
                    font-size:14pt; font-weight:bold"> </span><span
                    style="font-family:Calibri; font-size:14pt;
                    font-weight:bold; -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri; font-size:14pt;
                    font-weight:bold">Responsible Parties </span></p><p
                style="margin:6.55pt 319.25pt 0pt 0.05pt; line-height:18.2pt"><span
                    style="font-family:Calibri">Sponsor : </span><span
                    style="font-family:Calibri; font-weight:bold">LEO pharma
                    France </span><span style="font-family:Calibri">2 Rue René
                    Caudron </span></p><p style="margin:0.05pt 323.7pt 0pt
                0.05pt; line-height:18.35pt"><span style="font-family:Calibri">78960
                    Voisins-le-Bretonneux France </span></p><p
                style="margin:18.35pt 249pt 0pt 0.05pt; line-height:18.25pt"><span
                    style="font-family:Calibri">Study Sponsor Contact: Yassmina
                    Mandouri</span><span style="font-family:Calibri;
                    -aw-import:spaces">&#xa0; </span><span
                    style="font-family:Calibri">2 Rue René Caudron, </span></p><p
                style="margin-top:3.75pt; margin-left:0.05pt; margin-bottom:0pt;
                text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri">78960 Voisins-le-Bretonneux
                </span></p><p style="margin-top:3.75pt; margin-left:0.05pt;
                margin-bottom:0pt; text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri">Email yamfr @leo-pharma.com
                </span></p><p style="margin:18.4pt 262.45pt 0pt 0.05pt;
                line-height:18.2pt"><span style="font-family:Calibri">Contract
                    Research Organization: </span><span
                    style="font-family:Calibri; font-weight:bold">CLINACT</span><span
                    style="font-family:Calibri"> Vélizy Espace, bâtiment Santos
                    Dumont 13 Avenue Morane Saulnier </span></p><p
                style="margin-top:3.75pt; margin-left:0.05pt; margin-bottom:0pt;
                text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri">78140 Vélizy-Villacoublay
                </span></p><p style="margin:18.45pt 323.25pt 0pt 0.05pt;
                line-height:18.2pt"><span style="font-family:Calibri">Coordinating
                    Investigator: </span><span style="font-family:Calibri;
                    font-weight:bold">Dr Ziad REGUIAI</span><span
                    style="font-family:Calibri"> Polyclinique Reims-Bezannes 89
                    Rue Victor De Broglie 51430 Bezannes, FRANCE </span></p><p
                style="margin-top:40.35pt; margin-left:0.05pt;
                margin-bottom:0pt; text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri">Scientific committee: </span></p><p
                style="margin-top:3.65pt; margin-left:0.05pt; margin-bottom:0pt;
                text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri; font-weight:bold">Dr
                    Pierre-Dominique GHISLAIN </span></p><p style="margin:0.1pt
                132.35pt 0pt 0.05pt; line-height:18.35pt"><span
                    style="font-family:Calibri">Cliniques Universitaires Saint
                    Luc – Université Catholique de Louvain Avenue Hippocrate 10,
                </span></p><p style="margin-top:3.6pt; margin-left:0.05pt;
                margin-bottom:0pt; text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri">1200 Woluwe- Saint-Lambert
                </span></p><p style="margin-top:3.75pt; margin-left:0.05pt;
                margin-bottom:0pt; text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri; font-weight:bold">Dr Thierry
                    BOYE </span></p><p style="margin-top:3.65pt;
                margin-left:0.05pt; margin-bottom:0pt; text-align:justify;
                line-height:14.6pt"><span style="font-family:Calibri">Hôpital
                    d'Instruction des armées SAINTE ANNE (TOULON) </span></p><p
                style="margin-top:3.75pt; margin-left:0.05pt; margin-bottom:0pt;
                text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri">BCRM TOULON 2 boulevard Sainte
                    Anne BP 600 – 83800 TOULON Cedex 9 </span></p><p
                style="margin:0pt 323.25pt 0pt 0.05pt; line-height:18.2pt"><br
                    style="page-break-before:always; clear:both" /><span
                    style="font-family:Calibri; font-weight:bold">Dr Ziad
                    REGUIAI</span><span style="font-family:Calibri">
                    Polyclinique Reims-Bezannes 89 Rue Victor De Broglie 51430
                    Bezannes, France </span></p><p style="margin:18.4pt 9.8pt
                0pt 0.05pt; text-align:justify; line-height:18.2pt"><span
                    style="font-family:Calibri">LEO Pharma legal entity is the
                    sponsor of the study and the Contract Research
                    Organisation(s) (CRO) CLINACT is authorised by LEO to act on
                    behalf of LEO. LEO Pharma 2 Rue René Caudron, 78960
                    Voisins-le-Bretonneux, France will be the Data Controller.
                </span></p><p style="margin:0.2pt 9.85pt 0pt 0.05pt;
                text-align:justify; line-height:18.2pt"><span
                    style="font-family:Calibri">Contact and responsibilities of
                    all parties contributing to the study, including all
                    investigators, are detailed in a stand-alone document
                    available upon request to LEO. For key contributors, e.g.
                </span><span style="font-family:Calibri; letter-spacing:0.05pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">national </span><span
                    style="font-family:Calibri; letter-spacing:0.1pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">coordinating </span><span
                    style="font-family:Calibri; letter-spacing:0.05pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">investigators, </span><span
                    style="font-family:Calibri; letter-spacing:0.1pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">LEO </span><span
                    style="font-family:Calibri; letter-spacing:0.05pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">will </span><span
                    style="font-family:Calibri; letter-spacing:0.1pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">keep </span><span
                    style="font-family:Calibri; letter-spacing:0.1pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">CVs</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">and </span><span
                    style="font-family:Calibri; letter-spacing:0.1pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">documentation</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">regarding Conflicts of
                    Interest and make such documentation available upon request
                    from relevant parties, e.g. authorities, journals. LEO will
                    keep a record of all relevant sponsor personnel. CLINACT
                    will keep a record of all involved CRO personnel. </span></p><p
                style="margin:0.05pt 10.1pt 0pt 0.05pt; line-height:18.35pt"><span
                    style="font-family:Calibri">The following essential
                    documents must be in the hands of LEO before the study is
                    initiated at a site: </span></p><ul type="disc"
                style="margin:0pt; padding-left:0pt"><li
                    style="margin-right:9.9pt; margin-left:10.57pt;
                    line-height:18.35pt; padding-left:7.33pt; font-family:serif;
                    -aw-font-family:'Symbol'; -aw-font-weight:normal;
                    -aw-number-format:''"><span style="font-family:Calibri">Written
                        agreement between LEO or CLINACT and the Study Site
                        Responsible / Clinic / Hospital. </span></li><li
                    style="margin-top:0.05pt; margin-right:10.25pt;
                    margin-left:10.57pt; line-height:18.35pt;
                    padding-left:7.33pt; font-family:serif;
                    -aw-font-family:'Symbol'; -aw-font-weight:normal;
                    -aw-number-format:''"><span style="font-family:Calibri">Signed</span><span
                        style="font-family:Calibri; -aw-import:spaces">&#xa0;
                    </span><span style="font-family:Calibri">and</span><span
                        style="font-family:Calibri; -aw-import:spaces">&#xa0;
                    </span><span style="font-family:Calibri">dated</span><span
                        style="font-family:Calibri; -aw-import:spaces">&#xa0;
                    </span><span style="font-family:Calibri">protocol</span><span
                        style="font-family:Calibri; -aw-import:spaces">&#xa0;
                    </span><span style="font-family:Calibri">agreement</span><span
                        style="font-family:Calibri; -aw-import:spaces">&#xa0;
                    </span><span style="font-family:Calibri">and</span><span
                        style="font-family:Calibri; -aw-import:spaces">&#xa0;
                    </span><span style="font-family:Calibri">amendment</span><span
                        style="font-family:Calibri; -aw-import:spaces">&#xa0;
                    </span><span style="font-family:Calibri">agreements,</span><span
                        style="font-family:Calibri; -aw-import:spaces">&#xa0;
                    </span><span style="font-family:Calibri">if</span><span
                        style="font-family:Calibri; -aw-import:spaces">&#xa0;
                    </span><span style="font-family:Calibri">any,</span><span
                        style="font-family:Calibri; -aw-import:spaces">&#xa0;
                    </span><span style="font-family:Calibri">with</span><span
                        style="font-family:Calibri; -aw-import:spaces">&#xa0;
                    </span><span style="font-family:Calibri">the original
                        signature of the Site Responsible. </span></li><li
                    style="margin-right:10.15pt; margin-left:10.57pt;
                    line-height:18.35pt; padding-left:7.33pt; font-family:serif;
                    -aw-font-family:'Symbol'; -aw-font-weight:normal;
                    -aw-number-format:''"><span style="font-family:Calibri">Patient
                        Information Sheet and Informed Consent Form in local
                        language (notified to / approved by Independent Ethics
                        Committees (IECs). </span></li><li
                    style="margin-top:3.7pt; margin-left:10.57pt;
                    text-align:justify; line-height:14.6pt; padding-left:7.33pt;
                    font-family:serif; -aw-font-family:'Symbol';
                    -aw-font-weight:normal; -aw-number-format:''"><span
                        style="font-family:Calibri">Written IEC / IRB approval.
                    </span></li><li style="margin-top:3.7pt;
                    margin-left:10.57pt; text-align:justify; line-height:14.6pt;
                    padding-left:7.33pt; font-family:serif;
                    -aw-font-family:'Symbol'; -aw-font-weight:normal;
                    -aw-number-format:''"><span style="font-family:Calibri">Competent
                        Authority notification. </span></li><li
                    style="margin-top:3.7pt; margin-left:10.57pt;
                    text-align:justify; line-height:14.6pt; padding-left:7.33pt;
                    font-family:serif; -aw-font-family:'Symbol';
                    -aw-font-weight:normal; -aw-number-format:''"><span
                        style="font-family:Calibri">Product liability insurance.
                    </span></li><li style="margin-top:0.15pt;
                    margin-right:10.05pt; margin-left:10.57pt;
                    line-height:18.2pt; padding-left:7.33pt; font-family:serif;
                    -aw-font-family:'Symbol'; -aw-font-weight:normal;
                    -aw-number-format:''"><span style="font-family:Calibri">LEO
                        safety plan which is a three party agreement between
                        Global safety, Safety contact person and the CRO on the
                        handling of safety reporting</span></li></ul><p
                style="margin-top:3.05pt; margin-left:35.55pt;
                margin-bottom:0pt; text-align:justify; line-height:17.1pt"><br
                    style="page-break-before:always; clear:both" /><a
                    name="_page9_x68.00_y96.92"></a><span
                    style="font-family:Calibri; font-size:14pt;
                    font-weight:bold">4</span><span style="font-family:Arial;
                    font-size:14pt; font-weight:bold"> </span><span
                    style="font-family:Calibri; font-size:14pt;
                    font-weight:bold; -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri; font-size:14pt;
                    font-weight:bold">Abstract </span></p><p
                style="margin-top:10.15pt; margin-left:0.05pt;
                margin-bottom:0pt; text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri; font-weight:bold">Title </span></p><p
                style="margin:5.95pt 9.85pt 0pt 0.05pt; text-align:justify;
                line-height:18.35pt"><span style="font-family:Calibri">Evaluation
                    of the sensitivity and specificity, compared to DLQI as a
                    standard tool, of a novel QOL questionnaire (treat to the</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">Patient satiSfactiOn
                    TARGET in Psoriasis patients) among moderate to severe
                    psoriasis patients treated with brodalumab (Kyntheum®)
                </span></p><p style="margin-top:34pt; margin-left:0.05pt;
                margin-bottom:0pt; text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri; font-weight:bold">Rationale and
                    background</span><span style="font-family:Calibri"> </span></p><p
                style="margin:5.95pt 9.8pt 0pt 0.05pt; text-align:justify;
                line-height:18.35pt"><span style="font-family:Calibri">The
                    severity of psoriasis can be influenced by a great variety
                    of factors including extent of the disease, lesions location
                    and impact on quality of life. The current standard of care
                    for psoriasis is focusing on the reduction of the skin
                    symptoms as defined by the PASI, somewhat setting asides the
                    patient’s feelings in terms of which aspects of his/her life
                    are affected </span><span style="font-family:Calibri;
                    letter-spacing:0.4pt">by</span><span
                    style="font-family:Calibri"> the disease. Despite the fact
                    that multiple patient reported outcomes (PRO) questionnaires
                    are available to evaluate the impact of the disease on
                    patients’ quality of life, only few items address the
                    subjective impact of skin disease. Among the available PROs
                    the Dermatology Life Quality Index (DLQI) is the most
                    frequently used. It is a standardized tool designed to cover
                    a broad range of dermatologic afflictions but lacks
                    specificity towards the effect of psoriasis on quality of
                    life. The DLQI is composed of ten questions grouped in 6
                    domains “symptoms and feelings”, “daily activities”,
                    “leisure”, “work/school”, “personal relationships” and
                    “treatment”. Each answer is graded from 0 to 3. The DLQI
                    score</span><span style="font-family:Calibri;
                    letter-spacing:0.35pt"> </span><span
                    style="font-family:Calibri">is calculated by adding the
                    score of each question, resulting in a maximum score of 30
                    and a minimum of 0. The higher the score, the more quality
                    of life is impaired. A score higher than 10 indicates that
                    the patient's life is being severely affected by their skin
                    disease.</span><span style="font-family:Calibri;
                    -aw-import:spaces">&#xa0; </span></p><p style="margin:0pt
                9.85pt 0pt 0.05pt; text-align:justify; line-height:18.35pt"><span
                    style="font-family:Calibri">Because of its limitations, some
                    patients cannot seem to completely restore a normal quality
                    of life (e.g. DLQI 0-1) even though their reached a perfect
                    PASI score (100). This phenomenon may be explained by the
                    fact that the patient’s own perception can be different from
                    the physician’s perspective and may have changed in time,
                    between follow-ups. These are as many reasons as why it is
                    highly difficult to accurately fathom the therapeutic
                    expectations of the psoriasis patients. The standard tools
                    currently in use are not able to assess the perception of
                    the disease by the patient its evolution over time. In
                    addition, it is widely recognized that alexithymia is more
                    prevalent in the psoriasis patients than in the general
                    population and patients</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">with</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">alexithymia</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">appear</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">to</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">suffer</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">higher</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">psoriasis</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">burden</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">as</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">they</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">have</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">more difficulties to
                    express their expectations.</span><span> </span><span
                    style="font-family:Calibri">Since patients struggle to
                    recognize and verbalize their emotions, it can be useful and
                    informative to offer patients a variety of verbatim in which
                    they</span><span style="font-family:Calibri;
                    -aw-import:spaces">&#xa0; </span><span
                    style="font-family:Calibri">can</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">identify.</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">PSO-TARGET</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">is</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">an</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">exploratory</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">observational,</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">non-interventional</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">study aiming to
                    evaluate a novel approach of assessing psoriasis patients’
                    satisfaction towards their biologic treatment from a quality
                    of life standpoint by using a psoriasis-specific Quality of
                    Life assessment grid. </span></p><p style="margin-top:28pt;
                margin-left:0.05pt; margin-bottom:0pt; text-align:justify;
                line-height:14.6pt"><span style="font-family:Calibri;
                    font-weight:bold">Research question and objectives </span></p><p
                style="margin:5.9pt 9.95pt 0pt 0.05pt; text-indent:28.3pt;
                text-align:justify; line-height:18.35pt"><span
                    style="font-family:Calibri">The aim of this exploratory
                    study is to evaluate the sensitivity and specifity of the
                    PSO- TARGET QoL Component grid as part of a new approach for
                    assessing the level of achievement of </span><span
                    style="font-family:Calibri; letter-spacing:0.1pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">the</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">psoriasis</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">patient’s </span><span
                    style="font-family:Calibri; letter-spacing:0.05pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">therapeutic </span><span
                    style="font-family:Calibri; letter-spacing:0.1pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">goal, </span><span
                    style="font-family:Calibri; letter-spacing:0.1pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">identified</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">by </span><span
                    style="font-family:Calibri; letter-spacing:0.05pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">himself, </span><span
                    style="font-family:Calibri; letter-spacing:0.1pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">after </span><span
                    style="font-family:Calibri; letter-spacing:0.1pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">a </span><span
                    style="font-family:Calibri; letter-spacing:0.1pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">treatment </span><span
                    style="font-family:Calibri; letter-spacing:0.1pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">with Kyntheum®. This tool will
                </span><span style="font-family:Calibri; letter-spacing:0.1pt">be,</span><span
                    style="font-family:Calibri"> if validated, used by
                    physicians to devise a “Treat to patient satisfaction
                    target” strategy that better suits their patients’
                    expectations.</span><span style="font-family:Calibri;
                    -aw-import:spaces">&#xa0; </span></p><p style="margin:5.9pt
                9.75pt 0pt 0.05pt; text-indent:28.3pt; text-align:justify;
                line-height:18.35pt"><span style="font-family:Calibri">To
                    construct this new questionnaire, the first step was to
                    collect psoriasis</span><span style="font-family:Calibri;
                    -aw-import:spaces">&#xa0; </span><span
                    style="font-family:Calibri">patients’ feedback on what is
                    the aspect of their life that is the most impacted by the
                    disease and which is the one they would want to improve the
                    most. To this aim, a retrospective survey based on the
                </span><span style="font-family:Calibri; letter-spacing:0.1pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">recollection </span><span
                    style="font-family:Calibri; letter-spacing:0.1pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">and </span><span
                    style="font-family:Calibri; letter-spacing:0.1pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">experience</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">from </span><span
                    style="font-family:Calibri; letter-spacing:0.2pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">three </span><span
                    style="font-family:Calibri; letter-spacing:0.1pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">clinical </span><span
                    style="font-family:Calibri; letter-spacing:0.1pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">dermatologists </span><span
                    style="font-family:Calibri; letter-spacing:0.1pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">(two </span><span
                    style="font-family:Calibri; letter-spacing:0.1pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">French </span><span
                    style="font-family:Calibri; letter-spacing:0.1pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">and </span><span
                    style="font-family:Calibri; letter-spacing:0.1pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">one Belgian) of patient’s
                    expectations, has been conducted. The results of the survey
                    have been used to analyse the type of expectations provided
                    by the patients. Based on that analysis, the expert
                    dermatologists generated a grid containing 12 therapeutic
                    goals equally distributed into the four major psychometric
                    components classically used in quality of life studies in
                    patients with chronic diseases (physical, subjective,
                    relational/social and therapeutic). The proposed verbatim
                    was then reviewed by a psychologist to ensure that there was
                    a balance between the proposals; i.e. the vocabulary used
                    was neutral enough not to guide the choices. This first step
                    has therefore given rise to a QoL component grid that will
                    be administered to the patients prior to the initiation of a
                    systemic treatment (Kyntheum® / brodalumab) to set up a main
                    objective for the upcoming treatment. At 12-16 weeks the
                    patient will be asked to rate his/her level of satisfaction
                    in regard to the treatment objective defined prior to
                    treatment initiation using a four-point Likert scale (“very
                    satisfied”, “satisfied”, “unsatisfied”, “very unsatisfied”).
                    In order to evaluate the sensitivity and specificity of, the
                    PSO-TARGET QoL component grid, the patient will be asked to
                    fill in, prior the treatment introduction and during the
                    follow up visits, the DLQI questionnaire. The primary
                    objective of the study will be to estimate the level of
                    concordance of this satisfaction level based on the
                    PSO-TARGET QOL tool and the reference method in Quality of
                    Life for psoriasis patients; i.e. the DLQI, at the same time
                    point. This aim will be reached by comparing, at 12-16
                    weeks, the DLQI and the satisfaction level given by patients
                    in regard to their own treatment objective defined at
                    baseline using the PSO-TARGET </span></p><p
                style="margin:0pt 9.8pt 0pt 0.05pt; text-align:justify;
                line-height:18.2pt"><span style="font-family:Calibri">QoL
                    component grid. True Positive (TP), False Positive (FP),
                    True Negative </span><span style="font-family:Calibri;
                    letter-spacing:0.05pt">(TN)</span><span
                    style="font-family:Calibri"> and False Negative (FN) will be
                    defined using a contingency table. These quantitative
                    variables will be used to calculate the sensitivity
                    (proportion of actual satisfied patients that are correctly
                    identified as such) and specificity (proportion of actual
                    unsatisfied patients that are correctly identified as such)
                    of the PSO-TARGET QoL Component grid, compared to the
                    quality of life given by the DLQI. If these metrics reach a
                    certain threshold (85%), the PSO-TARGET QoL component grid
                    will be considered for additional studies in order to
                    validate it at a larger scale and further demonstrate it is
                    as much sound in assessing the patients’ quality of life as
                    the DLQI. </span></p><p style="margin:5.9pt 9.8pt 0pt
                0.05pt; text-indent:28.3pt; text-align:justify;
                line-height:18.35pt"><span style="font-family:Calibri">Because
                    of the fact that alexithymia is highly prevalent in
                    psoriasis patients, the grid will be administered to the
                    patient after he/she had spontaneously expressed his/her
                    treatment expectations. This should help the patient to
                    narrow down the specific goal where his/her expectation
                    belongs. In addition, as part of a secondary objective the
                    treating physician will also choose an item from the table
                    based on what he/she perceives in terms of patient’s
                    expectations without disclosing it to the patient. This will
                    allow us to evaluate the level of accordance</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">between</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">the</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">physician-chosen</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">and</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">the</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">patient-chosen</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">therapeutic</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">goal.</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">As another secondary
                    endpoint, the level of achievement of the therapeutic goal
                    will be assessed at 12/16 weeks and followed-up for 52 ± 4
                    weeks. Patients scoring the treatment as “satisfied or</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">very</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">satisfied”</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">will</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">be</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">considered</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">as</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">having</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">achieved</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">their</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">therapeutic</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">goal.</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">Another endpoint of
                    interest (secondary) will be to assess, after 12/16 weeks of
                    treatment, if the patient chooses a new therapeutic goal,
                    different from the one he initially defined. </span></p><p
                style="margin:0pt 9.7pt 0pt 0.05pt; text-indent:28.3pt;
                text-align:justify; line-height:18.35pt"><span
                    style="font-family:Calibri">It is important to note that,
                    this study being observational, none of the visits (baseline
                    and follow-ups) are specific to the trial but part of the
                    dermatologists’ standard of care in both countries (France
                    and Belgium). In addition, in order to limit variability in
                    terms of treatment profiles</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">(dosage</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">and</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">administration</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">schedule)</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">and</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">thus</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">to</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">keep</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">the</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">study</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">population</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">as homogenous as
                    possible, it has been decided to include only patients
                    treated by Kyntheum®, in other terms Kyntheum® treatment is
                    an accessory to the study but PSO-TARGET will not assess
                    Kyntheum® efficacy </span><span style="font-family:Calibri;
                    font-style:italic">per se</span><span
                    style="font-family:Calibri">. </span></p><p
                style="margin-top:15.6pt; margin-left:0.05pt; margin-bottom:0pt;
                text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri">The study objectives are the
                    following: </span></p><p style="margin-top:9.75pt;
                margin-left:0.05pt; margin-bottom:0pt; text-align:justify;
                line-height:14.6pt"><span style="font-family:Calibri">Primary
                    objective: </span></p><p style="margin:0.15pt 9.75pt 0pt
                0.05pt; text-align:justify; line-height:18.2pt"><span
                    style="font-family:Calibri">Assess at week 12/16, post
                    biologic treatment, the sensitivity and the specificity,
                    compared to DLQI as a standard tool, of the PSO-TARGET QoL
                    component grid as a novel approach aiming to evaluate the
                    patients’ satisfaction with regard of their treatment.
                </span></p><p style="margin-top:2.95pt; margin-left:0.05pt;
                margin-bottom:0pt; text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri">Secondary objectives: </span></p><p
                style="margin:0.05pt 17.25pt 0pt 18.05pt; text-indent:-18pt;
                text-align:justify; line-height:18.35pt; -aw-import:list-item;
                -aw-list-level-number:0; -aw-list-number-format:'-';
                -aw-list-number-styles:'bullet'; -aw-list-padding-sml:14.33pt"><span
                    style="-aw-import:ignore"><span style="font-family:Calibri">-</span><span
                        style="width:14.33pt; font:7pt 'Times New Roman';
                        display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;
                    </span></span><span style="font-family:Calibri">Evaluate at
                    week 12/16, post Kyntheum® treatment, the percentage of
                    patients who has achieved the main treatment goal they
                    identified in the QoL component grid at baseline. </span></p><p
                style="margin:0.15pt 17.3pt 0pt 18.05pt; text-indent:-18pt;
                line-height:18.2pt; -aw-import:list-item;
                -aw-list-level-number:0; -aw-list-number-format:'-';
                -aw-list-number-styles:'bullet'; -aw-list-padding-sml:14.33pt"><span
                    style="-aw-import:ignore"><span style="font-family:Calibri">-</span><span
                        style="width:14.33pt; font:7pt 'Times New Roman';
                        display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;
                    </span></span><span style="font-family:Calibri">Identification
                    of predictive factors (among baseline characteristics) of
                    the achievement of the main treatment goal; </span></p><p
                style="margin:0.15pt 17.5pt 0pt 18.05pt; text-indent:-18pt;
                line-height:18.2pt; -aw-import:list-item;
                -aw-list-level-number:0; -aw-list-number-format:'-';
                -aw-list-number-styles:'bullet'; -aw-list-padding-sml:14.33pt"><span
                    style="-aw-import:ignore"><span style="font-family:Calibri">-</span><span
                        style="width:14.33pt; font:7pt 'Times New Roman';
                        display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;
                    </span></span><span style="font-family:Calibri">Evaluate the
                    level of agreement between the dimensions reported by the
                    patient and by the treating physician; </span></p><p
                style="margin:0.2pt 17.35pt 0pt 18.05pt; text-indent:-18pt;
                line-height:18.2pt; -aw-import:list-item;
                -aw-list-level-number:0; -aw-list-number-format:'-';
                -aw-list-number-styles:'bullet'; -aw-list-padding-sml:14.33pt"><span
                    style="-aw-import:ignore"><span style="font-family:Calibri">-</span><span
                        style="width:14.33pt; font:7pt 'Times New Roman';
                        display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;
                    </span></span><span style="font-family:Calibri">Evaluate at
                    52 weeks the percentage of patients for whom the therapeutic
                    objective initially achieved at the 1</span><span
                    style="font-family:Calibri; font-size:8pt">st</span><span
                    style="font-family:Calibri"> follow-up visit is still
                    maintained; </span></p><p style="margin:0pt 17.2pt 0pt
                18.05pt; text-indent:-18pt; line-height:18.35pt;
                -aw-import:list-item; -aw-list-level-number:0;
                -aw-list-number-format:'-'; -aw-list-number-styles:'bullet';
                -aw-list-padding-sml:14.33pt"><span style="-aw-import:ignore"><span
                        style="font-family:Calibri">-</span><span
                        style="width:14.33pt; font:7pt 'Times New Roman';
                        display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;
                    </span></span><span style="font-family:Calibri">Evaluate the
                    percentage of patients who change their therapeutic
                    objective after 12/16 weeks of treatment; </span></p><p
                style="margin-top:3.6pt; margin-left:18.05pt; margin-bottom:0pt;
                text-indent:-18pt; text-align:justify; line-height:14.6pt;
                -aw-import:list-item; -aw-list-level-number:0;
                -aw-list-number-format:'-'; -aw-list-number-styles:'bullet';
                -aw-list-padding-sml:14.33pt"><span style="-aw-import:ignore"><span
                        style="font-family:Calibri">-</span><span
                        style="width:14.33pt; font:7pt 'Times New Roman';
                        display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;
                    </span></span><span style="font-family:Calibri">Follow the
                    evolution of the PASI score (at 12/16 and 52 weeks); </span></p><p
                style="margin:0.05pt 17.25pt 0pt 18.05pt; text-indent:-18pt;
                line-height:18.35pt; -aw-import:list-item;
                -aw-list-level-number:0; -aw-list-number-format:'-';
                -aw-list-number-styles:'bullet'; -aw-list-padding-sml:14.33pt"><span
                    style="-aw-import:ignore"><span style="font-family:Calibri">-</span><span
                        style="width:14.33pt; font:7pt 'Times New Roman';
                        display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;
                    </span></span><span style="font-family:Calibri">Level of
                    accordance between PASI 90/100 and the satisfaction level in
                    regard to the therapeutic objective set by the PSO-TARGET
                    QoL Component grid; </span></p><p style="margin-top:3.6pt;
                margin-left:18.05pt; margin-bottom:0pt; text-indent:-18pt;
                text-align:justify; line-height:14.6pt; -aw-import:list-item;
                -aw-list-level-number:0; -aw-list-number-format:'-';
                -aw-list-number-styles:'bullet'; -aw-list-padding-sml:14.33pt"><span
                    style="-aw-import:ignore"><span style="font-family:Calibri">-</span><span
                        style="width:14.33pt; font:7pt 'Times New Roman';
                        display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;
                    </span></span><span style="font-family:Calibri">Follow the
                    evolution of the DLQI score (at 12/16 and 52 weeks). </span></p><p
                style="margin-top:28pt; margin-left:0.05pt; margin-bottom:0pt;
                text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri; font-weight:bold">Study design
                </span></p><p style="margin:6.15pt 9.9pt 0pt 0.05pt;
                text-indent:28.3pt; text-align:justify; line-height:18.2pt"><span
                    style="font-family:Calibri">PSO-TARGET</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">is</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">an</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">observational,</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">non-interventional,</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">prospective,</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">multicentric,
                    international, European study requiring no change in the
                    patients’ standard of care (RIPH3 in France). </span></p><p
                style="margin-top:15.75pt; margin-left:0.05pt;
                margin-bottom:0pt; text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri; font-weight:bold">Population
                </span></p><p style="margin:5.95pt 9.9pt 0pt 0.05pt;
                text-indent:28.3pt; line-height:18.35pt"><span
                    style="font-family:Calibri">Adult</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">patients</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">suffering</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">from</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">moderate</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">to</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">severe </span><span
                    style="font-family:Calibri; font-style:italic;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri; font-style:italic">psoriasis</span><span
                    style="font-family:Calibri; font-style:italic;
                    -aw-import:spaces">&#xa0; </span><span
                    style="font-family:Calibri; font-style:italic">vulgaris</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">for</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">whom</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">the dermatologist
                    decided to prescribe a treatment with Kyntheum®. </span></p><p
                style="margin-top:15.65pt; margin-left:0.05pt;
                margin-bottom:0pt; text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri; font-weight:bold">Variables
                </span></p><p style="margin-top:9.75pt; margin-left:28.35pt;
                margin-bottom:0pt; text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri">Primary endpoint </span></p><p
                style="margin:0.15pt 17.25pt 0pt 18.05pt; text-indent:-18pt;
                text-align:justify; line-height:18.2pt; -aw-import:list-item;
                -aw-list-level-number:0; -aw-list-number-format:'-';
                -aw-list-number-styles:'bullet'; -aw-list-padding-sml:14.33pt"><span
                    style="-aw-import:ignore"><span style="font-family:Calibri">-</span><span
                        style="width:14.33pt; font:7pt 'Times New Roman';
                        display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;
                    </span></span><span style="font-family:Calibri">At 12/16
                    weeks, level of concordance between the satisfaction level
                    in regard to the therapeutic objective set by the</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">PSO-TARGET QoL
                    Component grid and the DLQI in assessing the impact of the
                    treatment on the patients’ quality of life. </span></p><p
                style="margin-top:21.65pt; margin-left:28.35pt;
                margin-bottom:0pt; text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri">Secondary endpoints </span></p><p
                style="margin:6.05pt 17.1pt 0pt 18.05pt; text-indent:-18pt;
                text-align:justify; line-height:18.35pt; -aw-import:list-item;
                -aw-list-level-number:0; -aw-list-number-format:'-';
                -aw-list-number-styles:'bullet'; -aw-list-padding-sml:14.33pt"><span
                    style="-aw-import:ignore"><span style="font-family:Calibri">-</span><span
                        style="width:14.33pt; font:7pt 'Times New Roman';
                        display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;
                    </span></span><span style="font-family:Calibri">At week
                    12/16, post Kyntheum® treatment, the percentage of patients
                    who achieved the main treatment goal identified by the
                    patient himself in the QoL component grid at baseline.</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">The</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">therapeutic</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">objective</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">achievement</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">is</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">defined</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">as</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">“satisfied”</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">or</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">“very satisfied”
                    response on 4 points Likert scale. </span></p><p
                style="margin:0.15pt 17.2pt 0pt 18.05pt; text-indent:-18pt;
                text-align:justify; line-height:18.15pt; -aw-import:list-item;
                -aw-list-level-number:0; -aw-list-number-format:'-';
                -aw-list-number-styles:'bullet'; -aw-list-padding-sml:14.33pt"><span
                    style="-aw-import:ignore"><span style="font-family:Calibri">-</span><span
                        style="width:14.33pt; font:7pt 'Times New Roman';
                        display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;
                    </span></span><span style="font-family:Calibri">Level</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">of</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">concordance</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">between</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">the</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">satisfaction</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">level</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">in</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">regard</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">to</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">the</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">therapeutic objective
                    set by the PSO-TARGET QoL Component grid and the DLQI at the
                    2</span><span style="font-family:Calibri; font-size:8pt">nd</span><span
                    style="font-family:Calibri"> follow-up visit (52 ± 4
                    weeks.). </span></p><p style="margin:0.15pt 17.25pt 0pt
                18.05pt; text-indent:-18pt; line-height:18.2pt;
                -aw-import:list-item; -aw-list-level-number:0;
                -aw-list-number-format:'-'; -aw-list-number-styles:'bullet';
                -aw-list-padding-sml:14.33pt"><span style="-aw-import:ignore"><span
                        style="font-family:Calibri">-</span><span
                        style="width:14.33pt; font:7pt 'Times New Roman';
                        display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;
                    </span></span><span style="font-family:Calibri">Research of
                    predictive factors (among baseline characteristics) of the
                    achievement of the main treatment goal. </span></p><p
                style="margin:0.05pt 17.25pt 0pt 18.05pt; text-indent:-18pt;
                line-height:18.35pt; -aw-import:list-item;
                -aw-list-level-number:0; -aw-list-number-format:'-';
                -aw-list-number-styles:'bullet'; -aw-list-padding-sml:14.33pt"><span
                    style="-aw-import:ignore"><span style="font-family:Calibri">-</span><span
                        style="width:14.33pt; font:7pt 'Times New Roman';
                        display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;
                    </span></span><span style="font-family:Calibri">Percentage</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">of</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">agreement</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">between</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">the</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">physician-reported</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">and</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">the</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">patient-reported
                    dimensions at the first follow-up visit. </span></p><p
                style="margin-top:3.45pt; margin-left:18.05pt;
                margin-bottom:0pt; text-indent:-18pt; text-align:justify;
                line-height:14.8pt; -aw-import:list-item;
                -aw-list-level-number:0; -aw-list-number-format:'-';
                -aw-list-number-styles:'bullet'; -aw-list-padding-sml:14.33pt"><span
                    style="-aw-import:ignore"><span style="font-family:Calibri">-</span><span
                        style="width:14.33pt; font:7pt 'Times New Roman';
                        display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;
                    </span></span><span style="font-family:Calibri">Rate of
                    patients having changed objective at the 1</span><span
                    style="font-family:Calibri; font-size:8pt">st</span><span
                    style="font-family:Calibri"> follow-up visit (12/ 16 weeks).
                </span></p><p style="margin:0.15pt 17.7pt 0pt 18.05pt;
                text-indent:-18pt; line-height:18.2pt; -aw-import:list-item;
                -aw-list-level-number:0; -aw-list-number-format:'-';
                -aw-list-number-styles:'bullet'; -aw-list-padding-sml:14.33pt"><span
                    style="-aw-import:ignore"><span style="font-family:Calibri">-</span><span
                        style="width:14.33pt; font:7pt 'Times New Roman';
                        display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;
                    </span></span><span style="font-family:Calibri">Percentage
                    of patients who have maintained at 52 ± 4 weeks the level of
                    satisfaction achieved at the 1st follow-up visit. </span></p><p
                style="margin:0.05pt 17.25pt 0pt 18.05pt; text-indent:-18pt;
                line-height:18.5pt; -aw-import:list-item;
                -aw-list-level-number:0; -aw-list-number-format:'-';
                -aw-list-number-styles:'bullet'; -aw-list-padding-sml:14.33pt"><span
                    style="-aw-import:ignore"><span style="font-family:Calibri">-</span><span
                        style="width:14.33pt; font:7pt 'Times New Roman';
                        display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;
                    </span></span><span style="font-family:Calibri">PASI Scores
                    at baseline, at the 1</span><span
                    style="font-family:Calibri; font-size:8pt">st</span><span
                    style="font-family:Calibri"> follow-up visit (12/ 16 weeks),
                    at the 2</span><span style="font-family:Calibri;
                    font-size:8pt">nd</span><span style="font-family:Calibri">
                    follow-up visit (52 ± 4 weeks.). </span></p><p
                style="margin:0.05pt 17.65pt 0pt 18.05pt; text-indent:-18pt;
                line-height:18.35pt; -aw-import:list-item;
                -aw-list-level-number:0; -aw-list-number-format:'-';
                -aw-list-number-styles:'bullet'; -aw-list-padding-sml:14.33pt"><span
                    style="-aw-import:ignore"><span style="font-family:Calibri">-</span><span
                        style="width:14.33pt; font:7pt 'Times New Roman';
                        display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;
                    </span></span><span style="font-family:Calibri">Level of
                    accordance between PASI 90/100 and the satisfaction level in
                    regard to the therapeutic objective set by the PSO-TARGET
                    QoL Component grid. </span></p><p style="margin:0pt 17.25pt
                0pt 18.05pt; text-indent:-18pt; line-height:18.55pt;
                -aw-import:list-item; -aw-list-level-number:0;
                -aw-list-number-format:'-'; -aw-list-number-styles:'bullet';
                -aw-list-padding-sml:14.33pt"><span style="-aw-import:ignore"><span
                        style="font-family:Calibri">-</span><span
                        style="width:14.33pt; font:7pt 'Times New Roman';
                        display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;
                    </span></span><span style="font-family:Calibri">DLQI Scores
                    at baseline, at the 1</span><span
                    style="font-family:Calibri; font-size:8pt">st</span><span
                    style="font-family:Calibri"> follow-up visit (12/ 16 weeks),
                    at the 2</span><span style="font-family:Calibri;
                    font-size:8pt">nd</span><span style="font-family:Calibri">
                    follow-up visit 52 ± 4 weeks. </span></p><p
                style="margin-top:27.95pt; margin-left:0.05pt;
                margin-bottom:0pt; text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri; font-weight:bold">Data sources
                </span></p><p style="margin:6.15pt 9.85pt 0pt 0.05pt;
                text-indent:28.3pt; line-height:18.2pt"><span
                    style="font-family:Calibri">Patients’ data will be collected
                    at day 0, at the 1</span><span style="font-family:Calibri;
                    font-size:8pt">st</span><span style="font-family:Calibri">
                    follow-up visit (12/16weeks) and at the 2</span><span
                    style="font-family:Calibri; font-size:8pt">nd</span><span
                    style="font-family:Calibri"> follow-up visit at 52 ± 4 weeks
                    according to the physician’s practice. </span></p><p
                style="margin:6.15pt 9.8pt 0pt 0.05pt; text-indent:28.3pt;
                text-align:justify; line-height:18.2pt"><span
                    style="font-family:Calibri">As a prospective study, </span><span
                    style="font-family:Calibri; letter-spacing:0.1pt">the</span><span
                    style="font-family:Calibri"> following data will be
                    collected during the patient visit: disease history,
                    concomitant treatments, previous anti psoriatic treatment
                    and adverse events. In addition, the following study
                    specific data will be collected: disease severity (PASI
                    score), quality of life questionnaires (DLQI, PSO-TARGET
                    component grid). </span></p><p style="margin-top:34pt;
                margin-left:0.05pt; margin-bottom:0pt; text-align:justify;
                line-height:14.6pt"><span style="font-family:Calibri;
                    font-weight:bold">Study size </span></p><p
                style="margin:9.75pt 10.1pt 0pt 0.05pt; text-align:justify;
                line-height:14.6pt"><span style="font-family:Calibri">The main
                    criterion is the sensitivity of the PSO-TARGET tool
                    (percentage of patients who consider their target objective
                    as being achieved after 12/16 weeks of treatment as defined
                    by a “satisfied or very satisfied” response, assessed on a 4
                    points Likert scale, among patients with a DLQI total score
                    of 0 or </span><span style="font-family:Calibri;
                    letter-spacing:0.05pt">1).</span><span
                    style="font-family:Calibri"> </span></p><p
                style="margin-top:6.05pt; margin-left:0.05pt; margin-bottom:0pt;
                text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri">The sample size calculation is
                    based on the following hypotheses : </span></p><p
                style="margin-top:3.1pt; margin-left:36.05pt; margin-bottom:0pt;
                text-indent:-18pt; text-align:justify; line-height:14.6pt;
                -aw-import:list-item; -aw-list-level-number:0;
                -aw-list-number-format:''; -aw-list-number-styles:'bullet';
                -aw-list-padding-sml:8.57pt"><span style="-aw-import:ignore"><span
                        style="font-family:Wingdings"></span><span
                        style="width:8.57pt; font:7pt 'Times New Roman';
                        display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;
                    </span></span><span style="font-family:Calibri">Sensitivity
                    : 90%</span><span style="font-family:Calibri;
                    -aw-import:spaces">&#xa0; </span></p><p
                style="margin-top:8.9pt; margin-left:36.05pt; margin-bottom:0pt;
                text-indent:-18pt; text-align:justify; line-height:14.6pt;
                -aw-import:list-item; -aw-list-level-number:0;
                -aw-list-number-format:''; -aw-list-number-styles:'bullet';
                -aw-list-padding-sml:8.57pt"><span style="-aw-import:ignore"><span
                        style="font-family:Wingdings"></span><span
                        style="width:8.57pt; font:7pt 'Times New Roman';
                        display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;
                    </span></span><span style="font-family:Calibri">Absolute
                    precision : 10% </span></p><p style="margin-top:9.05pt;
                margin-left:36.05pt; margin-bottom:0pt; text-indent:-18pt;
                text-align:justify; line-height:14.6pt; -aw-import:list-item;
                -aw-list-level-number:0; -aw-list-number-format:'';
                -aw-list-number-styles:'bullet'; -aw-list-padding-sml:8.57pt"><span
                    style="-aw-import:ignore"><span
                        style="font-family:Wingdings"></span><span
                        style="width:8.57pt; font:7pt 'Times New Roman';
                        display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;
                    </span></span><span style="font-family:Calibri">Type I error
                    : 5% </span></p><p style="margin-top:8.9pt;
                margin-left:36.05pt; margin-bottom:0pt; text-indent:-18pt;
                text-align:justify; line-height:14.6pt; -aw-import:list-item;
                -aw-list-level-number:0; -aw-list-number-format:'';
                -aw-list-number-styles:'bullet'; -aw-list-padding-sml:8.57pt"><span
                    style="-aw-import:ignore"><span
                        style="font-family:Wingdings"></span><span
                        style="width:8.57pt; font:7pt 'Times New Roman';
                        display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;
                    </span></span><span style="font-family:Calibri">Power at 80%</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span></p><p style="margin:6.15pt 10.05pt 0pt 36.05pt;
                text-indent:-18pt; line-height:17.5pt; -aw-import:list-item;
                -aw-list-level-number:0; -aw-list-number-format:'';
                -aw-list-number-styles:'bullet'; -aw-list-padding-sml:8.57pt"><span
                    style="-aw-import:ignore"><span
                        style="font-family:Wingdings"></span><span
                        style="width:8.57pt; font:7pt 'Times New Roman';
                        display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;
                    </span></span><span style="font-family:Calibri">Prevalence:</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">80%</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">(estimated</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">rate</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">of</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">patients</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">with</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">a</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">DLQI</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri; letter-spacing:0.05pt">0-1</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">after</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">12</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">weeks</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">of treatment. </span></p><p
                style="margin-top:9.05pt; margin-left:0.05pt; margin-bottom:0pt;
                text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri">Based on these hypotheses, the
                    sample size needed is estimated at 134 evaluable patients.
                </span></p><p style="margin:5.95pt 10pt 0pt 0.05pt;
                line-height:17.6pt"><span style="font-family:Calibri">Assuming
                    10% of patients will not be evaluable on main criterion,
                </span><span style="font-family:Calibri; font-weight:bold">150
                    patients have to be included.</span><span
                    style="font-family:Calibri"> </span></p><p
                style="margin-top:30.75pt; margin-left:0.05pt;
                margin-bottom:0pt; text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri; font-weight:bold">Data analysis
                </span></p><p style="margin-top:9.65pt; margin-left:0.05pt;
                margin-bottom:0pt; text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri; text-decoration:underline">Analysis
                    of the primary endpoint</span><span
                    style="font-family:Calibri"> </span></p><p
                style="margin:6.05pt 10.1pt 0pt 0.05pt; text-align:justify;
                line-height:18.35pt"><span style="font-family:Calibri">The
                    performance of the PSO-TARGET QoL component grid to assess
                    the treatment impact on the patients’ quality of life will
                    be determined by calculating the sensitivity and specificity
                    of the grid compared to the DLQI (reference). The grid will
                    be validated if both the specificity and sensitivity
                    parameters reach the 85% threshold. </span></p><p
                style="margin-top:33.95pt; margin-left:0.05pt;
                margin-bottom:0pt; text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri; font-weight:bold">Milestones
                </span></p><p style="margin:6.15pt 301.15pt 0pt 0.05pt;
                line-height:18.2pt"><span style="font-family:Calibri">Regulatory
                    Submissions: Q2 2020 Start of data collection Q3 2020</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">End of data collection
                </span><span style="font-family:Calibri; letter-spacing:0.05pt">Q2</span><span
                    style="font-family:Calibri"> 2022 Final report Q4 2022
                </span></p><p style="margin-top:9.9pt; margin-left:35.55pt;
                margin-bottom:0pt; text-align:justify; line-height:17.1pt"><a
                    name="_page14_x68.00_y568.92"></a><span
                    style="font-family:Calibri; font-size:14pt;
                    font-weight:bold">5</span><span style="font-family:Arial;
                    font-size:14pt; font-weight:bold"> </span><span
                    style="font-family:Calibri; font-size:14pt;
                    font-weight:bold; -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri; font-size:14pt;
                    font-weight:bold">Amendments and Updates </span></p><p
                style="margin-top:10.15pt; margin-left:0.05pt;
                margin-bottom:0pt; text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri">None </span></p><p
                style="margin-top:3.05pt; margin-left:35.55pt;
                margin-bottom:0pt; text-align:justify; line-height:17.1pt"><br
                    style="page-break-before:always; clear:both" /><a
                    name="_page15_x68.00_y96.92"></a><span
                    style="font-family:Calibri; font-size:14pt;
                    font-weight:bold">6</span><span style="font-family:Arial;
                    font-size:14pt; font-weight:bold"> </span><span
                    style="font-family:Calibri; font-size:14pt;
                    font-weight:bold; letter-spacing:15.5pt; -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri; font-size:14pt;
                    font-weight:bold">Milestones </span></p><p
                style="margin-top:10.15pt; margin-left:0.05pt;
                margin-bottom:0pt; text-align:justify; line-height:14.6pt"><span
                    style="font-family:Calibri">Planned dates for study
                    milestones are indicated in the table below: </span></p><p
                style="margin-top:21.1pt; margin-bottom:0pt; text-align:justify;
                line-height:1.1pt"><span style="font-family:Arial;
                    font-size:1pt; -aw-import:spaces">&#xa0;</span></p><table
                cellspacing="0" cellpadding="0" style="border:0.75pt solid
                #000000; -aw-border:0.5pt single; -aw-border-insideh:0.5pt
                single #000000; -aw-border-insidev:0.5pt single #000000;
                border-collapse:collapse"><tr style="height:18.85pt;
                    -aw-height-rule:exactly"><td style="width:57.9pt;
                        border-right-style:solid; border-right-width:0.75pt;
                        border-bottom-style:solid; border-bottom-width:0.75pt;
                        padding-right:76.18pt; padding-left:83.98pt;
                        vertical-align:top; -aw-border-bottom:0.5pt single;
                        -aw-border-right:0.5pt single"><p
                            style="margin-top:0.15pt; margin-bottom:0pt;
                            text-align:justify; line-height:14.6pt"><span
                                style="font-family:Calibri; font-size:12pt;
                                font-weight:bold">Milestone </span></p></td><td
                        style="width:74.55pt; border-left-style:solid;
                        border-left-width:0.75pt; border-bottom-style:solid;
                        border-bottom-width:0.75pt; padding-right:75.58pt;
                        padding-left:83.42pt; vertical-align:top;
                        -aw-border-bottom:0.5pt single; -aw-border-left:0.5pt
                        single"><p style="margin-top:0.15pt; margin-bottom:0pt;
                            text-align:justify; line-height:14.6pt"><span
                                style="font-family:Calibri; font-size:12pt;
                                font-weight:bold">Planned Date </span></p></td></tr><tr
                    style="height:18.85pt; -aw-height-rule:exactly"><td
                        style="width:118pt; border-top-style:solid;
                        border-top-width:0.75pt; border-right-style:solid;
                        border-right-width:0.75pt; border-bottom-style:solid;
                        border-bottom-width:0.75pt; padding-right:95.02pt;
                        padding-left:5.03pt; vertical-align:top;
                        -aw-border-bottom:0.5pt single; -aw-border-right:0.5pt
                        single; -aw-border-top:0.5pt single"><p
                            style="margin-top:0.15pt; margin-bottom:0pt;
                            text-align:justify; line-height:14.6pt"><span
                                style="font-family:Calibri; font-size:12pt">Start
                                of data collection </span></p></td><td
                        style="width:48.95pt; border-top-style:solid;
                        border-top-width:0.75pt; border-left-style:solid;
                        border-left-width:0.75pt; border-bottom-style:solid;
                        border-bottom-width:0.75pt; padding-right:179.58pt;
                        padding-left:5.03pt; vertical-align:top;
                        -aw-border-bottom:0.5pt single; -aw-border-left:0.5pt
                        single; -aw-border-top:0.5pt single"><p
                            style="margin-top:0.15pt; margin-bottom:0pt;
                            text-align:justify; line-height:14.6pt"><span
                                style="font-family:Calibri; font-size:12pt">Q3
                                2020 </span></p></td></tr><tr
                    style="height:18.7pt; -aw-height-rule:exactly"><td
                        style="width:113.15pt; border-top-style:solid;
                        border-top-width:0.75pt; border-right-style:solid;
                        border-right-width:0.75pt; border-bottom-style:solid;
                        border-bottom-width:0.75pt; padding-right:99.88pt;
                        padding-left:5.03pt; vertical-align:top;
                        -aw-border-bottom:0.5pt single; -aw-border-right:0.5pt
                        single; -aw-border-top:0.5pt single"><p
                            style="margin-top:0.15pt; margin-bottom:0pt;
                            text-align:justify; line-height:14.6pt"><span
                                style="font-family:Calibri; font-size:12pt">End
                                of data collection </span></p></td><td
                        style="width:49pt; border-top-style:solid;
                        border-top-width:0.75pt; border-left-style:solid;
                        border-left-width:0.75pt; border-bottom-style:solid;
                        border-bottom-width:0.75pt; padding-right:179.52pt;
                        padding-left:5.03pt; vertical-align:top;
                        -aw-border-bottom:0.5pt single; -aw-border-left:0.5pt
                        single; -aw-border-top:0.5pt single"><p
                            style="margin-top:0.15pt; margin-bottom:0pt;
                            text-align:justify; line-height:14.6pt"><span
                                style="font-family:Calibri; font-size:12pt">Q2
                                2022 </span></p></td></tr><tr
                    style="height:18.85pt; -aw-height-rule:exactly"><td
                        style="width:93.65pt; border-top-style:solid;
                        border-top-width:0.75pt; border-right-style:solid;
                        border-right-width:0.75pt; padding-right:119.38pt;
                        padding-left:5.03pt; vertical-align:top;
                        -aw-border-right:0.5pt single; -aw-border-top:0.5pt
                        single"><p style="margin-top:0.25pt; margin-bottom:0pt;
                            text-align:justify; line-height:14.6pt"><span
                                style="font-family:Calibri; font-size:12pt">Final
                                study report </span></p></td><td
                        style="width:49pt; border-top-style:solid;
                        border-top-width:0.75pt; border-left-style:solid;
                        border-left-width:0.75pt; padding-right:179.52pt;
                        padding-left:5.03pt; vertical-align:top;
                        -aw-border-left:0.5pt single; -aw-border-top:0.5pt
                        single"><p style="margin-top:0.25pt; margin-bottom:0pt;
                            text-align:justify; line-height:14.6pt"><span
                                style="font-family:Calibri; font-size:12pt">Q4
                                2022 </span></p></td></tr></table><p
                style="margin:14.7pt 9.95pt 0pt 0.05pt; text-align:justify;
                line-height:18.2pt"><span style="font-family:Calibri">The start
                    of the study is defined as the date on which the first
                    information on a study patient is recorded in the study
                    dataset. LEO will ensure that End-of-Data Collection (End of
                    Study) notification is submitted to the concerned
                    authorities and </span><span style="font-family:Calibri;
                    letter-spacing:0.05pt">IECs</span><span
                    style="font-family:Calibri"> for each site, for each country
                    and for the complete study. </span></p><p
                style="margin:0.05pt 10.2pt 0pt 0.05pt; line-height:18.35pt"><span
                    style="font-family:Calibri">Based on upcoming knowledge, LEO
                    might choose to terminate the study prematurely. In such
                    case the Committee(s), study sites, IECs and authorities
                    will be informed promptly. </span></p><p
                style="margin-top:32.05pt; margin-left:35.55pt;
                margin-bottom:0pt; text-align:justify; line-height:17.1pt"><a
                    name="_page15_x68.00_y392.92"></a><span
                    style="font-family:Calibri; font-size:14pt;
                    font-weight:bold">7</span><span style="font-family:Arial;
                    font-size:14pt; font-weight:bold"> </span><span
                    style="font-family:Calibri; font-size:14pt;
                    font-weight:bold; letter-spacing:15.5pt; -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri; font-size:14pt;
                    font-weight:bold">Rationale and Background </span></p><p
                style="margin:6.45pt 9.8pt 0pt 0.05pt; text-align:justify;
                line-height:18.35pt"><span style="font-family:Calibri">Psoriasis
                    is a chronic, immune-mediated inflammatory skin disease.
                    Clinical manifestations of psoriasis can be of multiple
                    forms, including, among others, plaque psoriasis, guttate
                    psoriasis, palmoplantar psoriasis, and pustular psoriasis
                    (Lebwohl, 2018). Psoriasis is characterized by an abnormal
                    keratinocyte proliferation in the interfollicular epidermis
                    along with an infiltration of</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">antigen-presenting</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">cells</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">and</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">release</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">of</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">pro</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">inflammatory</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">cytokines,</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">leading</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">to</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">a</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">local inflammation
                    (Ippagunta et al., 2016; Lowes et al., </span><span
                    style="font-family:Calibri; letter-spacing:0.05pt">2007).</span><span
                    style="font-family:Calibri"> The aetiology of the disease is
                    not fully understood, but a number of risk factors are
                    recognized, including family history and environmental risk
                    factors, such as smoking, stress, obesity, and alcohol
                    consumption (Huerta et al., 2007). The prevalence of
                    psoriasis is difficult to evaluate with precision but is
                    estimated around 2-4% in western countries (Gelfand et al.,
                    2005; Kurd and Gelfand, 2009; Stern et al., 2004). In
                    France, the prevalence of psoriasis is estimated to 4,4 %</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">(Richard et al., 2018).
                    Psoriasis</span><span style="font-family:Calibri;
                    -aw-import:spaces">&#xa0; </span><span
                    style="font-family:Calibri">causes</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">considerable
                    psychosocial</span><span style="font-family:Calibri;
                    -aw-import:spaces">&#xa0; </span><span
                    style="font-family:Calibri">disability</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">and</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">has</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">a</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">major</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">impact</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">on patients’ quality of
                    life (Krueger et al., 2001). </span></p><p style="margin:0pt
                9.8pt 0pt 0.05pt; text-align:justify; line-height:18.35pt"><span
                    style="font-family:Calibri">The severity of psoriasis can be
                    influenced by a great variety of factors including extent of
                    the disease, inflammation, lesions location and impact on
                    quality of life. As those factors can fluctuate over time,
                    so can the intensity of the disease and more importantly the
                    patient’s perception of his/her affliction. The current
                    standard of care for treatment of psoriasis is </span></p><p
                style="margin:0pt 7.25pt 0pt 0.05pt; line-height:18.2pt"><span
                    style="font-family:Calibri">primarily focusing on the
                    reduction of the skin symptoms as defined by the Psoriasis
                    Area Severity Index (PASI), somewhat setting asides the
                    patient’s feelings in terms of which aspects of his/her life
                    are affected by the disease. Indeed, a multinational study
                    has already shown that a discrepancy exists between the
                    physician’s assessment of the disease severity and the
                    patient’s (van de Kerkhof et al., 2015). This could be, at
                    least partially, explained by the use of standardized tools,
                    by the physician which not necessarily take into
                    consideration the patients therapeutic expectation which
                    could sometimes be a subjective parameter. (van de Kerkhof
                    et al., 2015). Currently, the higher efficacy observed with
                    new biologics means that PASI 90 or even PASI 100 response
                    are increasingly being considered as a new treatment goal
                    (Daudén et al., 2016; Kerdel and Zaiac, 2015; Lebwohl et
                    al., </span><span style="font-family:Calibri;
                    letter-spacing:0.05pt">2015).</span><span
                    style="font-family:Calibri"> However, other quality of life
                    aspects of chronic affections such as psoriasis that are not
                    being assessed by tools like the PASI, must not be
                    overlooked Multiple patient reported outcomes (PRO)
                    questionnaires are available to evaluate the impact of the
                    disease on patients’ quality of life. Among the available
                    PROs, the Dermatology Life Quality Index (DLQI) is the most
                    frequently used (Puig et al., 2017). It is composed of ten
                    questions grouped in 6 domains “symptoms and feelings”,
                    “daily activities”, “leisure”, “work/school”, “personal
                    relationships” and “treatment”. Each answer is graded from 0
                    to 3. T</span><span>he </span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">DLQI is calculated by adding the
                    score of each question, resulting in a maximum of 30 and a
                    minimum of 0. The higher the score, the more quality of life
                    is impaired. A score higher than 10 indicates that the
                    patient's life is being severely affected by their skin
                    disease (Finlay and Khan, 1994). However, </span><span
                    style="font-family:Calibri; letter-spacing:0.05pt">the</span><span
                    style="font-family:Calibri"> DLQI is a standardized tool
                    which missing potentially some quality of life specific
                    issues for psoriasis patient. Consequently, among patients,
                    some cannot seem to completely restore a normal quality of
                    life (DLQI </span><span style="font-family:Calibri;
                    letter-spacing:0.15pt">0-1)</span><span
                    style="font-family:Calibri"> even though they reached a
                    perfect PASI score (100). This phenomenon may be explained
                    by the fact that the patient’s own perception can be
                    different from the physician’s perspective and may have
                    changed between follow-ups. Although, </span><span
                    style="font-family:Calibri; letter-spacing:0.05pt">the</span><span
                    style="font-family:Calibri"> Patient Benefit Index has been
                    devised to allow the patient to weigh the therapeutic goals
                    in order to define which ones are the most important</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">for</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">him/her</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">(using</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">a</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">4</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">points</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">Likert</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">Scale,</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">(Augustin</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">et</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">al.,</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">2008)),</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">it</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">is</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">not discriminatory
                    enough towards the patient’s principal expectation
                    (Feuerhahn et al., 2012). In addition, </span><span
                    style="font-family:Calibri; letter-spacing:0.05pt">it</span><span
                    style="font-family:Calibri"> is widely recognized that
                    alexithymia (difficulty to express emotion) is more
                    prevalent in the psoriasis patients than in the general
                    population and psoriasis patients with alexithymia appear to
                    suffer higher psoriasis burden as they have more
                    difficulties to express their expectations (Sampogna et al.,
                    2017).</span><span> </span><span
                    style="font-family:Calibri">Since these patients struggle to
                    recognize and verbalize their emotions, it can be useful and
                    informative to offer patients a variety of verbatim in which
                    they can identify. Taken together these elements plea for a
                    novel approach that take more into consideration the
                    patient’s expectations prior to treatment initiation and not
                    only</span><span style="font-family:Calibri;
                    -aw-import:spaces">&#xa0; </span></p><p style="margin:0pt
                9.8pt 0pt 0.05pt; text-align:justify; line-height:18.2pt"><span
                    style="font-family:Calibri">the dermatologist symptomatic
                    approach. We therefore believe that it is of importance to
                    assess the 4 components of quality of life usually impacted
                    in case of chronic disease as defined by Chassany (Chassany,
                    2003; Forestier et al., 2019), before initiating the
                    systemic treatment, in order to define better therapeutics
                    goals in an holistic approach. It is necessary to assess
                    this new approach in a homogenous population, thus only
                    patients starting a biologic treatment by Kyntheum® at the
                    inclusion in the study will be enrolled. Indeed,
                    satisfaction towards a treatment may </span><span
                    style="font-family:Calibri; letter-spacing:0.05pt">be</span><span
                    style="font-family:Calibri"> influenced by several factors
                    including administration regimen.</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span></p><p style="margin:18.55pt 9.7pt 0pt 0.05pt;
                text-indent:28.3pt; text-align:justify; line-height:18.2pt"><span
                    style="font-family:Calibri">The aim of this study is to
                    evaluate, compared to the DLQI as a standard tool, the
                    sensitivity and specificity of the PSO-TARGET QoL Component
                    grid as a new QoL questionnaire for assessing the level of
                    satisfaction of the psoriasis patients in achieving the
                    therapeutic goal, identified by himself, after a biologic
                    treatment. This study is the first step of </span><span
                    style="font-family:Calibri; letter-spacing:0.1pt">an</span><span
                    style="font-family:Calibri"> evaluation process aiming to
                    validate the PSO-TARGET QoL Component grid. Ultimately, this
                    tool will be used by physicians to devise a “Treat to
                    patient satisfaction target” strategy that better suits
                    their patients’ expectations. To construct this new
                    questionnaire, the first step has been to collect psoriasis
                    patients’ feedback on what is the aspect of their life that
                    is the most impacted by the disease and which is the one
                    they would want to improve the most. To this aim a
                    retrospective survey based on the recollection and
                    experience from 3 clinical dermatologists (2 French and 1
                    Belgian) of patient’s expectations, was conducted. The
                    results of the survey have been used to generate a table
                    containing 12 treatment goals equally distributed into the 4
                    major</span><span style="font-family:Calibri;
                    -aw-import:spaces">&#xa0; </span><span
                    style="font-family:Calibri">components classically used in
                    quality of life studies in patients suffering from chronic
                    diseases (physical, subjective, relational/social and
                    therapeutic) (Chassany, 2003; Forestier et al., 2019). The
                    proposed verbatim was then reviewed by a psychologist to
                    ensure that there was a balance between the proposals; i.e.
                    the vocabulary used was neutral enough not to guide the
                    choices. This component grid will be administered to the
                    patients prior to the initiation of a systemic treatment
                    (Kyntheum® / brodalumab) to set up the main therapeutic
                    objective (1 out of 12) fitting with his priority
                    expectation from the upcoming treatment. The patient will
                    only have access to the 12 treatment goals but not to the
                    category headings. Because of the fact that alexithymia is
                    highly prevalent in psoriasis patients, the grid will be
                    submitted</span><span style="font-family:Calibri;
                    -aw-import:spaces">&#xa0; </span><span
                    style="font-family:Calibri">to</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">the</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">patient</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">after</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">he/she</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">had</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">been</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">asked</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">by</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">the</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">physician</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">to</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">express spontaneously
                    his/her treatment expectations. This should help the patient
                    to narrow down the item where his/her expectation belongs.
                    At the 1st follow-up visit (12/16 weeks), the level of
                    achievement will be assessed using a 4 points Likert scale</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">(“very satisfied”,
                    “satisfied”, “unsatisfied”, “very unsatisfied”). In order to
                    evaluate the sensitivity and the specificity of the
                    PSO-TARGET QoL component grid, the primary objective of the
                    study will be to estimate the </span></p><p
                style="margin:0pt 9.95pt 0pt 0.05pt; text-align:justify;
                line-height:18.2pt"><span style="font-family:Calibri">level of
                    concordance of this satisfaction level and the overall
                    quality of life as defined by the DLQI at the same time
                    point. It is important to consider that systemic treatment
                    by Kyntheum® is an accessory to the study but the objective
                    of the PSO-TARGET is not to evaluate Kyntheum® efficacy.
                </span></p><p style="margin:11.9pt 9.8pt 0pt 0.05pt;
                text-indent:28.3pt; text-align:justify; line-height:18.35pt"><span
                    style="font-family:Calibri">As part of secondary objectives,
                    in parallel to that initial assessment by the patient, the
                    physician will tick on the grid what would be his patients
                    therapeutic goal based on what he knows/understands from the
                    patient’s disease history and therapeutic desires. At the
                    time of his/her assessment, the physician will be blinded of
                    the patient’s choice of therapeutic goal. The accordance
                    between the physician-chosen and the patient-chosen
                    dimensions will be analyzed. The 12 items of the tool will
                    be pooled and analysed by component</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">(physical, subjective,
                    relational and therapeutic). At 52 weeks, among other
                    secondary endpoints, the maintenance of the level of
                    achievement of the initial objective observed at the </span><span
                    style="font-family:Calibri; letter-spacing:0.15pt">1</span><span
                    style="font-family:Calibri; font-size:8pt;
                    letter-spacing:0.15pt">st</span><span
                    style="font-family:Calibri"> follow-up visit, will be
                    assessed. </span></p><p style="margin:0.15pt 9.8pt 0pt
                0.05pt; text-indent:28.3pt; text-align:justify;
                line-height:18.2pt"><span style="font-family:Calibri">One</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">of</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">the</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">innovative</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">aspects</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">of</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">this</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">exploratory</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">observational</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">study</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">will</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">be</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">the administration of a
                    psoriasis-specific quality of life component grid containing
                    12 treatment objectives grouped in the 4 quality of life
                    components/dimensions usually impacted in patients suffering
                    from chronic diseases (Chassany, 2003; Forestier et al.,
                    2019). Those dimensions accounting for the burden to bear
                    when suffering from a chronic disease are the following:
                    Physical, Subjective, Relational/Social and Therapeutic.
                    Each dimension will include 3 patient’s therapeutic goal
                    based on dermatologists’ clinical experience and reviewed by
                    an expert on psychometric tools. </span></p><p
                style="margin:0.05pt 9.7pt 0pt 0.05pt; text-align:justify;
                line-height:18.35pt"><span style="font-family:Calibri">This is
                    an exploratory study, a first step to assess the interest of
                    the PSO-TARGET component grid. If the sensitivity and
                    specificity reach an acceptable threshold (85%), the
                    potential of the PSO-TARGET grid will be</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span><span style="font-family:Calibri">considered for
                    validation in larger clinical studies. Indeed, more studies
                    will be needed to test other attributes in order to fully
                    validate the PSO-TARGET grid as an alternative to the DLQI
                    for QoL assessment. Once the PSO-TARGET component grid is
                    validated, it will prove to be a useful tool for a better
                    design of a therapeutic objective from the physician and
                    thus a better care brought to the patient which should
                    improve the patient’s satisfaction and treatment adherence.</span><span
                    style="font-family:Calibri; -aw-import:spaces">&#xa0;
                </span></p><br style="page-break-before:always; clear:both" /><p
                style="margin:0pt 196.9pt 0pt 0.15pt; text-indent:35.4pt;
                line-height:27.35pt"><a name="_page19_x68.00_y96.92"></a><span
                    style="font-family:Calibri; font-size:14pt;
                    font-weight:bold">8</span><span style="font-family:Arial;
                    font-size:14pt; font-weight:bold"> </span><span
                    style="font-family:Calibri; font-size:14pt;
                    font-weight:bold; letter-spacing:15.5pt; -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri; font-size:14pt;
                    font-weight:bold">Research Question and Objectives</span><span
                    style="font-family:Calibri; font-size:14pt;
                    font-weight:bold; font-style:italic"> </span><span
                    style="font-family:Calibri; font-size:14pt;
                    font-weight:bold; -aw-import:spaces">&#xa0;</span><img
                    src="Output.046.png" width="24" height="14" alt=""
                    style="-aw-left-pos:0pt; -aw-rel-hpos:column;
                    -aw-rel-vpos:paragraph; -aw-top-pos:0pt;
                    -aw-wrap-type:inline" /><a name="_page19_x68.00_y123.92"></a><span
                    style="font-family:Arial; font-size:14pt; font-weight:bold">
                </span><span style="font-family:Calibri; font-size:14pt;
                    font-weight:bold; letter-spacing:1.7pt; -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri; font-size:14pt;
                    font-weight:bold">Primary Objective </span></p><p
                style="margin:6.4pt 10pt 0pt 0.05pt; text-align:justify;
                line-height:18.35pt"><span style="font-family:Calibri">The
                    primary endpoint will be the evaluation at week 12/16 of the
                    sensitivity and the specificity, compared to the DLQI as a
                    standard, of the PSO-TARGET QoL component grid to assess the
                    level of satisfaction of patient achieving the therapeutic
                    goal, identified by himself. </span></p><p
                style="margin:12.1pt 10.15pt 0pt 0.05pt; text-align:justify;
                line-height:18.25pt"><span style="font-family:Calibri">The
                    therapeutic objective will be considered as achieved if the
                    patient gives the responses “Satisfied” or “Very Satisfied”
                    on the Likert scale. The response will then be compared to
                    the DLQI score at 12/16 weeks. </span></p><p
                style="margin-top:21.7pt; margin-left:0.15pt;
                margin-bottom:6.45pt; text-align:justify; font-size:14pt"><img
                    src="Output.047.png" width="24" height="14" alt=""
                    style="-aw-left-pos:0pt; -aw-rel-hpos:column;
                    -aw-rel-vpos:paragraph; -aw-top-pos:0pt;
                    -aw-wrap-type:inline" /><a name="_page19_x68.00_y291.92"></a><span
                    style="font-family:Arial; font-weight:bold"> </span><span
                    style="font-family:Calibri; font-weight:bold;
                    letter-spacing:1.7pt; -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri; font-weight:bold">Secondary
                    Objectives </span></p><p style="margin:0.3pt 17.55pt 0pt
                18.05pt; text-indent:-18pt; line-height:18.35pt;
                -aw-import:list-item; -aw-list-level-number:0;
                -aw-list-number-format:'-'; -aw-list-number-styles:'bullet';
                -aw-list-padding-sml:14.33pt"><span style="-aw-import:ignore"><span
                        style="font-family:Calibri">-</span><span
                        style="width:14.33pt; font:7pt 'Times New Roman';
                        display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;
                    </span></span><span style="font-family:Calibri">Evaluate the
                    percentage of patients who consider their target objective
                    as being achieved after 12/16 weeks of treatment as defined
                    by a “satisfied or very satisfied” response. </span></p><p
                style="margin:0.3pt 17.2pt 0pt 18.05pt; text-indent:-18pt;
                text-align:justify; line-height:18.05pt; -aw-import:list-item;
                -aw-list-level-number:0; -aw-list-number-format:'-';
                -aw-list-number-styles:'bullet'; -aw-list-padding-sml:14.33pt"><span
                    style="-aw-import:ignore"><span style="font-family:Calibri">-</span><span
                        style="width:14.33pt; font:7pt 'Times New Roman';
                        display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;
                    </span></span><span style="font-family:Calibri">Level
                </span><span style="font-family:Calibri; letter-spacing:0.85pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">of </span><span
                    style="font-family:Calibri; letter-spacing:0.8pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">concordance </span><span
                    style="font-family:Calibri; letter-spacing:0.7pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">between </span><span
                    style="font-family:Calibri; letter-spacing:0.85pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">the </span><span
                    style="font-family:Calibri; letter-spacing:0.85pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">satisfaction </span><span
                    style="font-family:Calibri; letter-spacing:0.8pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">level </span><span
                    style="font-family:Calibri; letter-spacing:0.85pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">in </span><span
                    style="font-family:Calibri; letter-spacing:0.8pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">regard </span><span
                    style="font-family:Calibri; letter-spacing:0.7pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">to </span><span
                    style="font-family:Calibri; letter-spacing:0.85pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">the </span><span
                    style="font-family:Calibri; letter-spacing:0.8pt;
                    -aw-import:spaces">&#xa0;</span><span
                    style="font-family:Calibri">therapeutic objective set by the
                    PSO-TARGET QoL Component grid and the DLQI at the 2</span><span
                    style="font-family:Calibri; font-size:8pt">nd</span><span
                    style="font-family:Calibri"> follow-up visit (52 ± 4
                    weeks.). </span></p><p style="margin:0pt 17.35pt 0pt
                18.05pt; text-indent:-18pt; line-height:18.35pt;
                -aw-import:list-item; -aw-list-level-number:0;
                -aw-list-number-format:'-'; -aw-list-number-styles:'bullet';
                -aw-list-padding-sml:14.33pt"><span style="-aw-import:ignore"><span
                        style="font-family:Calibri">-</span><span
                        style="width:14.33pt; font:7pt 'Times New Roman';
                        display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;
                    </span></span><span style="font-family:Calibri">Evaluate the
                    level of agreement between the dimensions reported by the
                    patient and by the treating physician at baseline. </span></p><p
                style="margin:0.15pt 17.6pt 0pt 18.05pt; text-indent:-18pt;
                line-height:18.2pt; -aw-import:list-item;
                -aw-list-level-number:0; -aw-list-number-format:'-';
                -aw-list-number-styles:'bullet'; -aw-list-padding-sml:14.33pt"><span
                    style="-aw-import:ignore"><span style="font-family:Calibri">-</span><span
                        style="width:14.33pt; font:7pt 'Times New Roman';
                        display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;
                    </span></span><span style="font-family:Calibri">Follow the
                    degree of completeness of the main treatment goal identified
                    at baseline after 52 weeks. </span></p><p
                style="margin-top:3.75pt; margin-left:18.05pt;
                margin-bottom:0pt; text-indent:-18pt; text-align:justify;
                line-height:14.6pt; -aw-import:list-item;
                -aw-list-level-number:0; -aw-list-number-format:'-';
                -aw-list-number-styles:'bullet'; -aw-list-padding-sml:14.33pt"><span
                    style="-aw-import:ignore"><span style="font-family:Calibri">-</span><span
                        style="width:14.33pt; font:7pt 'Times New Roman';
                        display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;
                    </span></span><span style="font-family:Calibri">Follow
                    evolution of the PASI score (at 12/16 and 52 weeks). </span></p><p
                style="margin-top:0pt; margin-bottom:0pt"><span
                    style="font-weight:bold; color:#ff0000">This document was
                    truncated here because it was created in the Evaluation
                    Mode.</span></p><div
                style="-aw-headerfooter-type:footer-primary; clear:both"><p
                    style="margin-top:0pt; margin-bottom:0pt"><span
                        style="font-weight:bold; color:#ff0000">Created with an
                        evaluation copy of Aspose.Words. To discover the full
                        versions of our APIs please visit:
                        https://products.aspose.com/words/</span></p><p
                    style="margin:0pt 21pt 0pt 48.05pt; line-height:6.95pt"><span
                        style="height:0pt; display:block; position:absolute;
                        z-index:-65537"><img src="Output.004.png" width="46"
                            height="29" alt="" style="margin-top:-7.08pt;
                            margin-left:-44.55pt; -aw-left-pos:74.4pt;
                            -aw-rel-hpos:page; -aw-rel-vpos:paragraph;
                            -aw-top-pos:-0.13pt; -aw-wrap-type:none;
                            position:absolute" /></span><span style="height:0pt;
                        display:block; position:absolute; z-index:-65538"><img
                            src="Output.003.png" width="4" height="35" alt=""
                            style="margin-top:-8.88pt; margin-left:-4.95pt;
                            -aw-left-pos:114pt; -aw-rel-hpos:page;
                            -aw-rel-vpos:paragraph; -aw-top-pos:-1.93pt;
                            -aw-wrap-type:none; position:absolute" /></span><span
                        style="font-size:6pt">THIS DOCUMENT CONTAINS TRADE
                        SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION,
                        PRIVILEGED OR CONFIDENTIAL, </span><span
                        style="font-size:6pt; letter-spacing:0.05pt">DELI-
                    </span><span style="font-size:6pt">VERED IN CONFIDENCE AND
                        RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR
                        MADE AVAILABLE TO ANY THIRD PARTY WITHOUT THE WRITTEN
                        CONSENT OF LEO PHARMA A/S </span></p></div></div></body></html>